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Abstract: A great challenge to clinical development is the delivery of chemotherapeutic agents, known to cause severe toxic effects, 
directly to diseased sites which increase the therapeutic index whilst minimizing off-target side effects. Antibody-conjugated 
nanoparticles offer great opportunities to overcome these limitations in therapeutics. They combine the advantages given by the 
nanoparticles with the ability to bind to their target with high affinity and improve cell penetration given by the antibodies. This 
specialized vehicle, that can encapsulate several chemotherapeutic agents, can be engineered to possess the desirable properties, allowing 
overcoming the successive physiological conditions and to cross biological barriers and reach a specific tissue or cell. Moreover, 
antibody-conjugated nanoparticles have shown the ability to be internalized through receptor-mediated endocytosis and accumulate in 
cells without being recognized by the P-glycoprotein, one of the main mediators of multi-drug resistance, resulting in an increase in the 
intracellular concentration of drugs. Also, progress in antibody engineering has allowed the manipulation of the basic antibody structure 
for raising and tailoring specificity and functionality. This review explores recent developments on active drug targeting by nanoparticles 
functionalized with monoclonal antibodies (polymeric micelles, liposomes and polymeric nanoparticles) and summarizes the 
opportunities of these targeting strategies in the therapy of serious diseases (cancer, inflammatory diseases, infectious diseases, and 
thrombosis). 
Keywords: Active targeting, antibody-conjugated nanoparticles, infectious diseases therapy, inflammatory diseases therapy, surface 
modification, targeted drug delivery, tumour therapy. 
1. INTRODUCTION 
Many new classes of drugs are being discovered and rational 
designed to treat severe diseases. However, they are often restricted 
by dose-limiting toxicity and exhibit poor specificity in reaching the 
desired organ/tissue/cell. A great challenge to clinical development 
is delivering these drugs precisely and safely to the sites they are 
needed at the proper dose for the required amount of time, therefore 
achieving the maximum therapeutic effect. The recent advances in 
nanotechnology have a great potential to improve the prevention, 
diagnosis, and treatment of human diseases. Cell targeting 
therapeutics conjugating specific recognizing units such as 
antibodies will allow to increase therapeutic efficacy and to 
decrease systemic adverse effects. This approach is of great interest 
in oncology, pharmacology, and nanomedicine. 
2. TARGETED DRUG DELIVERY 
The combination of targeted delivery and controlled drug 
release technology offer numerous advantages in chemotherapy: 
greater efficacy, because optimal concentration of active drug can 
be maintained on the desired local site thus decreasing the toxic 
side effects, and greater convenience because fewer applications or 
treatments are needed [1]. Nanoparticles (NPs) offer enormous 
advantages to be used as drug carriers due to their dimension and 
physical-chemical properties. A schematic presentation of a NP is 
shown in Fig. (1a). Their size ranging from 20 nm to 200 nm allows 
them to circulate in the blood or stay in the body for long periods, 
to pass through cell membranes and be internalized. Their high 
surface/volume ratio allows the incorporation of large amounts of 
two or more drugs for combination therapy, or for the 
simultaneously delivery of two or more therapeutic modalities such 
as radiation and drugs causing lower systemic toxicity when 
compared with drugs in solution, since drugs are encapsulated and 
biologically unavailable during transit in systemic circulation [2]. 
They can also improve the solubility of hydrophobic compounds, 
which has significant implications because more than 40 % of 
active substances being identified through combinatorial screening  
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programs are poorly soluble in water [3], and offer a protection 
against drug degradation and an enhancement in the stability of 
drugs such as peptides, oligonucleotides, DNA and RNA 
molecules, and so forth. Another advantage is the facilitation of 
drug delivery across various barriers, the most important of which 
is the blood brain barrier (BBB). NPs currently used include 
liposomes (L), polymeric nanoparticles (PNP), polymeric micelles 
(PM), dendrimers, gold NPs, quantum dots, carbon nanotubes, and 
nanofibers [4-8]. 
For an efficient treatment, the ideal drug carrier would have the 
ability to deliver the drug in the desired cell/tissue/organ - target. 
Targeted of therapeutic NPs in a cell-, tissue-, or disease-specific 
manner represents a potentially powerful technology [9, 10]. 
Systemic delivery of targeted NPs presents great multidisciplinary 
challenges where for developing an effective drug delivery vehicle 
NPs must be engineered to possess the desirable properties capable 
of overcoming the successive physiological barriers/conditions they 
will encounter in their way to reach the target, and the ability to 
recognize the target cell, deliver the drug, or be internalized. This 
recognition capacity can be achieved by exploring the altered 
physiology of the diseased cells and tissues. Using smart materials, 
drug release can be triggered by the environment or other external 
events such as changes in pH and temperature that generally 
occurred in tumour tissues, the presence of an analyte such as 
glucose that occurred in diabetes or the increase in temperature that 
accompanies the inflammatory process. A more specific recognition 
can be obtained through molecules that are uniquely expressed or 
overexpressed by disease cells such as specific antigens, a 
carbohydrate or surface receptors. NPs may be functionalized by 
conjugating specific units such as antibody, lectins, peptides, 
proteins, DNA or RNA aptamers, and small molecules able to 
recognize those entities therefore delivering the drug to the desired 
target cells [9, 11] - active targeting - further increasing their 
specificity and efficacy. There has been an intensive research in the 
development of NPs as effective drug delivery systems for medical 
practice, especially for chemotherapy and gene delivery to which 
progresses in NP technology, material science, and cellular and 
molecular physiology and pathology have contributed [1, 12-19]. 
Monoclonal antibodies (MAbs) were the first class of targeting 
molecules and have been preferentially used due to their high 
affinity, specificity, and versatility. The development of chimeric, 
humanized and more recently the fully human antibodies or 
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fragments produced in transgenic animals or through phage display 
technique [20, 21] has partially solved the rapid opsonization and 
immunogenicity caused with the first mouse MAbs used. 
Due to the complexity of the body and its barriers, the 
efficiency of targeting NP accumulation to a specific cell/tissue/ 
organ is still a challenge. Effective targeting would require a dual 
focus strategy, a better understanding of the target/receptor and a 
simultaneous development of the targeting system.  
Some therapeutic conjugates are now under clinical 
development or in clinical practice. However, the success has been 
largely limited to ligand-drug conjugates and attempts have been 
made to enhance these systems by encapsulating the therapeutic 
agents in NPs.  
This review will focus on drug targeting strategies to treat 
severe diseases based on NPs surface functionalized with MAbs 
with potential clinical relevance. Different therapeutic applications 
and possibilities regarding PNP, L, and PM which have been 
conjugated with antibodies for the purpose of targeting therapy will 
be analyzed. The current statues of development will be reviewed 
and the challenges for developing improved drug delivery systems 
will be highlighted. 
3. MONOCLONAL ANTIBODIES AS TARGETING MOLE-
CULES 
MAbs were first shown to be able to bind to specific tumour 
antigens in 1975 [22] but their use in cancer treatment took many 
years. The emergence of recombinant technologies has 
revolutionized the selection and production of MAbs, allowing the 
design of fully human antibodies of any specificity and for diverse 
purposes. Recombinant antibodies can be engineered with 
optimized properties, such as antigen-binding affinity, molecular 
architecture, and dimerization state, and fused with a vast array of 
effector moieties to enhance their cell-targeting ability and potency 
[20, 22]. 
3.1. Antibody Engineering 
Antibodies or immunoglobulins occur naturally as part of the 
immune system of mammals by recognizing antigens and are 
produced by plasma B-cells [23]. The development of antibody 
engineering systems started in 1975 with the production of MAbs 
by the mouse hybridoma technology [22]. Since then, and with the 
need for antibodies with unique specificity and biopharmaceutical-
grade, antibodies and derived structures have been produced at 
large scale for various biomedical applications. The mouse 
hybridoma technology represents an almost universal method to 
produce antibodies against any desired antigen. This technology 
relies on the fusion of spleen cells from an immunized animal with 
myeloma cells to obtain hybridoma cells. Clones producing the 
desired MAbs are then further selected and screened. The majority 
of MAbs produced by hybridoma technology are murine 
monoclonal antibodies (MuMAbs), which are immunogenic when 
used as therapeutics in humans [24]. The induced human anti-
mouse antibody (HAMA) response quickly reduces the 
effectiveness of therapy by clearing the murine antibody from the 
bloodstream. The generation of human monoclonal antibodies 
(HuMAbs) may be performed either by immortalization of human 
B-lymphocytes and subsequent fusion with neoplastic cells (fusion 
partners), or by transformation with Epstein-Barr virus. However, 
human hybridoma technology has been restricted by inefficient 
immortalization procedures and the ethically unacceptable 
immunization of humans [24]. The combination of hybridoma 
technology [22] with recombinant DNA technology and valuable 
display techniques [25, 26] made possible, in the 80s, the 
construction of humanized antibodies [27] with desirable 
affinity/specificity and low immunogenicity [28]. Over the last 
years, resources were therefore directed towards genetically 
engineering the basic immunoglobulin structure in order to produce 
new and versatile therapeutic agents. 
3.2. Structure of Antibodies 
Antibodies possess a similar basic structure in a Y form (Fig. 
2a) of bifunctional molecules with two identical domains for 
antigen recognition (Fab fragment), and two identical domains (Fc 
fragment) [29] involved in effector functions and biodistribution of 
the antibody, linked via the flexible hinge region. These regions are 
part of two pairs of polypeptide chains folded into compact globular 


















Fig. (1). (a) Schematic illustration of a multi-functional NPs. (b) NP drug delivery and internalization via RME. Specific antibodies on the NP surface bind to 
cell-surface receptors, which trigger internalization of the NPs into the cell. The drug will be released intracellulary on exposure to lysosomal enzymes or 
lower pH. Drug-loaded NPs bypass the P-glycoprotein efflux pump leading to high intracellular drug concentration. 
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constant and variable regions. The main differences observed in the 
variable regions are located in three small hypervariable sequences, 
responsible for antigen binding, the so-called complementary 
determining regions (CDR), and corresponding to the N-terminal 
regions of the light and heavy chains (Fab portion) [23]. Antibodies 
bind to target molecules with high affinity and specificity. The 
antigen-binding region is highly specific, and varies among the 
antibodies. Thousands of millions of different antibodies can be 
generated, each one with a distinct specificity [29]. 
3.3. Engineered Antibody Structures 
A chimeric antibody is a combination of sequences from 
different species; the most common ones are those with a fully 
human sequence except for the variable regions, which are of 
murine origin. A chimeric antibody is an artificial molecule where 
the constant portions of the heavy and light chains are from a 
human IgG, and the variable regions, VH and VL, are obtained 
from a mouse or rat MAb. The aim of this construction is to reduce 
the immunogenicity of the mouse or rat antibodies, without 
affecting the specificity of the original antibody [29]. Efforts to 
reduce the immunogenicity of chimeric antibodies led to the 
creation, between 1988 and 1991, of “humanized” antibodies. 
These antibodies are less immunogenic, more effective and have a 
longer half-life than chimeric antibodies (4-15 days) [30, 31]. In 
humanized antibodies, only some small regions of the variable 
domains (called hypervariable regions or CDRs) belong to the 
original species, and the remainder has human sequences. The use 
of fully human MAbs reduces the possibility of an immune 
response. Human immunoglobulins interact better with human 
effector systems than antibodies of murine origin; there are 
differences associated to the distinct patterns of glycosylation 
among different species, which can affect the effectiveness of the 
antibody as a therapeutic agent; and the half-life of these antibodies 
is longer (11-24 days) [29].  
Antibodies can also be engineered to obtain compact and 
multivalent structures as single-chain Fv antibody fragments (scFv), 
diabodies, triabodies, bispecifics, minibodies [32] (Fig. 2b). 
Antibody fragments offer some advantages over intact antibodies in 
therapy. For instance, the speed of penetration by fragments is 
smaller than an intact antibody [9]. scFv incorporate a polypeptide 
chain to link VH and VL. This linker, of around 15 amino acids, 
has the necessary length and flexibility to permit an adequate 
spatial orientation of the VH and VL domains, generating a 
functional Fv of around 25 kD. Changing the linker length between 
V-domains creates new types of Fv modules [33]. If the linker is 5-
12 residues long, a scFv molecule is constrained to associate with a 
second scFv to form a dimer [34]; and the VH and VL domains 
have the same specificity, the product obtained is a bivalent 
homodimer known as a diabody [35]. Using the same technique, it 
is possible to produce recombinant molecules with two different 
specificities, called bispecific antibodies [25]. If the linker length is 
below 3 residues, three scFvs are forced to associate into a trivalent 
dimer (triabody) or a tetramer, depending on linker length, 
composition and V domain orientation [36] (Fig. 2b). Minibodies 
are minimized antibody-like β-proteins that recognize target 
molecules with high specificity and affinity. This polypeptide has a 
length of 61 amino acid residues and adopts a conformation that has 
an antigen-binding ability, and appears to show excellent 
pharmacokinetic properties in tumours [37]. The phage display of 
minibodies has allowed the discovery of inhibitors to important 
biomolecules [38-40]. It has also been shown that scFvs selected 
from phage display can be improved into analogous minibody 
structures [41]. 
Today, over 200 delivery systems based on antibodies or their 
fragments are in preclinical or clinical trials [11, 42]. Some have 
already undergone clinical development and have been successful 
translated into the clinical environment. The first therapeutic 
antibody approved by FDA was rituximab (Rituxan®), which binds 
to CD20 for treating B-cell lymphoma, in 1977. However, the fact 
that some patients do not respond to the initial treatment or exhibit 
relapses over time has pushed this monotherapy towards a 
combination with chemotherapeutic agents. The conjugation of 
chemotherapeutic agents onto MAbs using a reversible linker is 
limited to less than ten drug molecules. So, in attempt to increase 
drug loading capacity and to provide some protection to these 
drugs, drugs can be encapsulated into NPs and the particle surface 
functionalized with MAbs to maintain targeting efficacy. While 
being therapeutic agents in their own right, these antibodies also 
have the ability to serve as recognizing units when attached to drug 
delivery systems for even more effective therapies. The feasibility 
of antibody based tissue targeting has been clinically demonstrated 
over the past two decades and was reviewed by Mehren and Weiner 
[43], and Weiner and Adams [43, 44]. 
Trastuzumab or Herceptin®, which binds to HER-2, approved 
by FDA in 1998 for treating breast cancer, and rituximab have been 
conjugated to poly(lactic acid) (PLA) NPs, and the resulting 
conjugates exhibit a six-fold increase in the rate of particles uptake 
when compared with NPs without the MAb targeting molecule [45, 
46]. 
4. ANTIBODY FUNCTIONALIZED NANOPARTICLES 
Effective antibody-conjugated NPs must have the desirable 
properties capable to overcome the successive physiological 
barriers/conditions they will encounter in their way to reach the 
target, the ability to recognize and actively bind to target cells 
through specific antibody-receptor interactions, and being 
internalized when an intracellular delivery is intended. Antibody-
conjugated NPs for therapeutic applications include among others 











Fig. (2). (a) Structure of an IgG molecule. (b) Genetic construction of different antibody fragments. 
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4.1. Polymeric Micelles 
PM are super-molecular assemblies of amphiphilic copolymers 
that spontaneously associate in an aqueous phase. Their diameter 
does not exceed 100 nm and possess a core-shell structure. The core 
is composed of hydrophobic polymer blocks that can accommodate 
hydrophobic drugs, and the shell is a hydrophilic brush-like corona 
that makes the micelle water soluble, thereby allowing the delivery 
of the poorly soluble content. The attractive force leading to 
micellization is based on an interaction between the hydrophobic 
and electrostatically neutral parts of copolymers. Self-assembly 
starts when the copolymer concentration reaches the critical micelle 
concentration which is usually very low, increasing the likelihood 
of preserving the micellar structure after extreme dilution following 
intravenous administration to patients [47]. The hydrophobic blocks 
generally used are polyesters such as PLA, poly(ε-caprolactone) 
(PCL); poly(L-amino acid) such as poly(aspartic acid) and 
poly(glutamic acid); and, phospholipids such as phosphatidyl-
ethanolamine. The hydrophilic blocks commonly used are 
poly(ethylene glycol) (PEG) and poly(vinylpyrrolidone). 
PM have several advantages over other drug delivery systems, 
including increased drug solubility, prolonged circulation half-life, 
and lower toxicity. However, at the present time this technology 
lacks the ability to control the release of the entrapped agents. 
Currently, SP1049C [a formulation of doxorubicin (DOX)-
encapsulated pluronic micelles], NK911 [DOX-encapsulated 
micelles from a copolymer of PEG-DOX-conjugated poly(aspartic 
acid)], and Genexol-PM (a paclitaxel-encapsulated PEG-PLA 
micelle formulation) have been approved for clinical use [48]. 
4.2. Liposomes 
L are vesicles composed of one (unilamellar) or several 
(multilamellar) phospholipid bilayers surrounding an internal 
aqueous compartment. They can incorporate both hydrophilic and 
hydrophobic substances in the internal aqueous phase and in the 
lipid bilayer, respectively. They are widely used because of their 
size, amphiphatic character, and tissue biocompatibility. The 
techniques of preparation have often been described in literature. 
Briefly, lipids are dissolved in an organic solvent. After evaporation 
of the solvent, a dry lipid film is obtained and is then dispersed in 
an aqueous phase. The different preparation procedures differ 
according to the method used to disperse the lipids (thin lipid film 
hydration, mechanical methods such as sonication, extrusion, etc.). 
Lipids generally used are cholesterol and phosphatidylcholine. The 
in vivo use of conventional L, however, is hampered by their rapid 
clearance from the circulation by the reticuloendothelial system 
(RES) [49] but extended circulation time can be achieved by 
grafting highly hydrophilic chains (e.g., PEG) to the surface of the 
L. Moreover, some L components inhibit the improvement of P-
glycoprotein (P-gp) and consequently allow to reach a higher drug 
concentration inside the cells and show permeability across the 
BBB [50]. 
A Stealth® liposomal formulation of the anticancer drug DOX 
(Doxil®/Caelyx®) was the first L delivery system to gain FDA 
approval in 1995 [51, 52] for the treatment of Kaposi’s cancer and 
ovarian cancer. Other examples include DaunoXome® (dauno-
rubicin L), DepotDur® (morphine L), and Ambisome® (amphoteri-
cine B L) [53]. Although no antibody-conjugated L [immunolipo-
somes (IL)] are yet in clinical use, extensive preclinical research 
activity is taking place in this area. However, some potential 
drawbacks like batch-to-batch variation in manufacturing, low drug 
loading efficiency, and poor stability can limit their market. 
4.3. Polymeric Nanoparticles 
PNP can be fabricated from a variety of biocompatible 
polymeric materials and hold sufficient strength and durability, 
which are a very important properties for many modes of targeting. 
PNP can encapsulate drugs or a combination of drugs, and release 
them in a controlled manner via diffusion of the drug through the 
polymer matrix, particle surface or bulk erosion, swelling followed 
by diffusion or in response to the local environment. Drug release 
mechanisms depend on the type/properties of the carrier and the 
type of interactions established between the drug and the polymeric 
matrix, and were extensively reviewed by Arifin et al. [54]. 
Consequently, it is possible to control the release rate and design 
these drug delivery systems by changing the NP properties. The 
release of the active agent may be constant over a long period, or 
may be triggered by the environment or other external events. In 
general, these systems can provide drug levels at an optimum range 
over a long period of time than other drug delivery methods, thus 
increasing the efficacy of the drug and maximizing patient 
compliance [55]. Polymers have a wide range of molecular weight 
and varying chemical composition which contribute to their 
versatility in structure and properties. Co-polymers and polymer 
blends can be adjusted to design the drug delivery vehicle for a 
specific application. Polymer blends also allow the production of 
particles containing two layers, commonly known as double walled 
particles, with advantages for clinical applications as they have the 
ability to deliver more than one drug or other active agent in a 
sequential manner and show a lower initial burst release [56-58]. 
Both natural (albumin, chitosan, heparin, etc.) as synthetic 
[PLA, poly (lactic-co-glycolic acid) (PLGA), poly(L-glutamate), 
PEG) biodegradable polymers are being exploited in drug delivery 
systems. Polymers or co-polymers comprising PLA, poly(glycolic 
acid), PLGA, PCL, PEG and poly(methyl methacrylate) have 
shown good histocompatibility and biodegradability, and are 
approved by the Food and Drug Administration (FDA) [59]. PLA, 
PGA, and their copolymer PLGA are the most commonly used 
biocompatible polymers for controlled release of drugs and have 
been extensively reviewed in the past [60-62]. 
Stimuli responsive polymers - smart polymers - can also be 
used to get target site delivery where drug release or cell 
internalization can be triggered by the environment or other 
external events. Stimuli may occur internally such as a change in 
pH in certain tissues or diseased states, a change in temperature or 
the presence of specific enzymes [63]. In tumour tissues, the pH can 
decrease to approximately 6.6 when compared to physiologic pH 
(7.4) therefore triggering the drug release. Micelles of PLA-b-PEG-
b-poly(L-histidine) triblock copolymer with a pKa of 7.0 have 
shown to release the drug at the slightly acidic tumour extracellular 
matrix [64]. NPs of glycol chitosan containing camptothecin have 
shown an accumulation 2 to 3 times higher at the tumour site than 
at the other organs and exhibited significant tumour effects [65-67]. 
Moreover, after cellular uptake, the drug can be released from the 
polymeric carrier under the acidic lysosomal pH (4.5 to 5.0) [68]. 
The most common pH sensitive polymers studied include 
poly(methacrylic acid), poly(acrylic acid), and poly(acrylamide) 
[69, 70]. Also, temperature sensitive polymers can be used to 
produce drug carriers that will release the incorporated drug at 
temperatures higher than the critical solution temperature at which 
their physical state changes. An interesting application of thermo-
responsive carriers is in hyperthermia treatment of cancer which is 
usually performed at 42 ºC [71, 72], and in the treatment of 
inflammatory tissues. Thus, thermo-responsive drug carriers should 
have their critical solution temperature above the 37 ºC of the 
healthy body, and as close to 42 ºC as possible. Examples of 
temperature-responsive polymers are poly(N-isopropylacrylamide), 
and poly(N-(1)-1-hydroxymethylpropylmethacrylamide) [63, 73]. 
Methods of preparation of NPs can be divided in two major 
classes, one dealing with monomers polymerization whereas the 
other involves dispersion of polymers such as salting out, solvent 
emulsification/diffusion, and nanoprecipitation [74], all involving 
chemical engineering techniques [17]. Higher entrapment efficiency 
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can be achieved by incorporation of the drug during the process 
fabrication rather than adsorption on prepared NPs. PNP are mainly 
prepared using the emulsion/solvent evaporation technique or the 
precipitation solvent diffusion technique. In the first method, 
polymers are dissolved in an organic solvent immiscible to water 
(such as dicloromethane, chloroform, ethyl acetate) and emulsified 
in an aqueous phase generally containing an emulsifying agent 
[mainly poly(vinyl alcohol) (PVA) and sodium cholate] by high 
speed homogeneization or sonication to make an oil-in-water 
emulsion. Hydrophobic compounds (drug or else) to be 
incorporated are dissolved in the organic phase. For water soluble 
drugs, the technique is slightly modified to form a water-in-oil-in-
water emulsion [75]. The emulsion is then stirred to completely 
extract/evaporate the organic solvent and harden the particles that 
are collected by centrifugation or filtration. The formed particles 
can be freeze-dried to form dry powders for storage. In this method, 
the polymer type and molecular weight, the co-polymer blend ratio, 
the type of organic solvent, the drug amount, the type and 
concentration of stabilizer, the mechanical strength of mixing, and 
the organic/aqueous volume ratio used are key parameters, and 
determine the drug loading, size, and superficial charge of the 
produced NPs, crucial properties for NP fate in vivo. The most 
common emulsifier used is PVA. More efficient emulsifiers such as 
gelatine, poloxamers, polysorbates, etc. have also been reported in 
literature. Feng and co-workers have studied the effect of several 
type and concentrations of emulsifiers on particle properties, and 
show that saturated phospholipids are 40-fold more efficient than 
PVA and that vitamin E TPGS can result in a drug encapsulation 
efficiency as high as 100 % [76, 77]. In the nanoprecipitation 
method, polymers are dissolved in an organic solvent miscible with 
water (such as acetone or ethanol) and dispersed in an aqueous 
phase generally containing a colloid stabilizer. The almost 
instantaneous diffusion of the organic solvent into the aqueous 
phase results in polymer precipitation as NPs [78, 79]. Finally, the 
solvent is evaporated off or extracted by dialysis against water. In 
principle, only compounds soluble in the organic solvent can be 
incorporated using the second method. In order to avoid using toxic 
organic solvents supercritical fluid technology has also been 
applied [80-83]. 
NPs can aggregate during storage and subsequent dispersion. 
NPs with the absolute value of the zeta potential above 30 mV have 
been shown to be stable in suspension, as a larger amount of charge 
will enhance the repellent interaction among the particles, thereby 
stabilizing the NPs dispersed in the buffer [84]. 
4.4. Nanoparticle Properties 
An important consideration in the development of nanocarrier 
systems is the biological behaviour of the nanocarrier constituents 
and the potential for toxicity, especially upon chronic 
administration. NP biodistribution is largely determined by their 
physical and chemical properties such as particle size and surface 
characteristics which makes the production of NP with the 
appropriate properties a main issue. The effect of NP size 
distribution is non-linear and varies from organ to organ, 
underscoring the importance of tuning NP size for each distinct in 
vivo application. After administration, NP will usually be taken up 
by the liver, spleen, and other parts of the RES depending on their 
size and surface characteristics [9]. The size of NP should be large 
enough (> 10 nm) to prevent elimination by the glomerular 
excretion of kidneys [85] and their rapid leakage into blood 
capillaries, but small enough to escape capture by RES 
macrophages. Ideally, the size of an engineered-long circulatory 
particle should not exceed 200 nm to bypass the human splenic 
filtration process [86]. If greater than 200 nm and not deformable, 
particles may act as splenotropic agents [86].  
Apart from the size of NP, their surface hydrophobic character 
and electrical charge are key factors for the in vivo fate of carriers 
[87]. Particles with hydrophobic surfaces are easily recognized by 
the body immune system, and are then cleared by phagocytes from 
the circulation. Once in the blood, the size of NP can increase 
significantly, as a result of particle aggregation and adsorption of 
blood components mainly proteins (opsonins) capable of interacting 
with specific plasma membrane receptors on monocytes and 
various subsets of tissue macrophages, thus promoting particle 
recognition by these cells [9] and accumulation in the organs of the 
mononuclear phagocyte system (MPS) (liver, spleen, lungs, and 
bone marrow) [18]. Particles of different surface charge, size, and 
morphology will attract different types of opsonins and other blood 
proteins which may determine the recognition process and therefore 
account for the different rate and sites of particle clearance. The 
interaction with proteins can also interfere with other biological 
processes such as the blood-clotting cascade because of 
complement activation [88]. Neutral L (100 nm or below), show a 
longer circulation time in rats (half-lives up to 20 h) than their 
anionic counterparts (half-lives less than 1 h) which may be due to 
a non-efficient coating with the opsonizing complement proteins 
resulting in a poor recognition by Küpffer cells [89]. However, in 
the case of larger neutral or anionic Ls, clearance rates increased 
progressively with increasing size [90]. Therefore, if the organs of 
the MPS and hepatocytes are not the intended site of action than NP 
should be in the range of 120 to 200 nm in diameter [9], and have a 
hydrophilic surface in order to increase the likelihood of the success 
to reach the targeted cell/tissue [91]. Surface modification of NPs 
can be achieved by coating the NP surface with hydrophilic 
surfactants such as PEG, poloxamines, poloxamers, poly(vinyl 
pyrrolidone), and polysaccharides which not only improve the 
biocompatibility but also the resistance to protein adsorption 
increasing blood circulation time and target cell efficiency [9, 92, 
93]. This can be performed by adsorption, incorporation during NP 
production, or by covalent attachment to the surface. Alternatively, 
NPs can be formed from block copolymers with hydrophilic and 
hydrophobic domains such as PEG-co-polymers. Stealth micelle 
formulations have stabilizing PEG coronas to minimize 
opsonization of the micelles and maximize serum half-life. In 
humans, a 200-fold decrease of the systemic plasma clearance was 
observed for PEGylated Ls in comparison to conventional Ls [94]. 
Also, the half-life of gelatine NPs increased from 3 to 15 h when 
they were PEGylated [95]. Long-circulating NPs of PCL containing 
tamoxifen and surface-modified with poly(ethylene oxide) chains 
have shown an enhanced blood circulation time and tumour 
targeting after intravenous injection in mice bearing MDA-MB-231 
xenografts, a human breast cancer cell line [96]. Adjusting the ratio 
of polymer groups/types and using different surfactants and 
stabilizers, NPs with the desirable properties can be developed to 
carry the drug to target cells. Studies with tracking of single NP are 
providing new insights into the interactions and processes involved 
in the transport of drug carriers in vivo using fluorescence 
nanocrystals (quantum dots) [97]. 
4.5. Nanoparticle Functionalization with Antibodies 
The selection of the antibody as the target recognizing ligand to 
attach onto NP surface is crucial for the optimal design of targeted 
NPs. It should have a high affinity and specificity towards the 
appropriate target surface marker. To maximize specificity, the 
surface marker (antigen or receptor) should be ideally unique and 
homogeneously expressed or overexpressed on target cells relative 
to normal cells [11]. For example in a breast cancer model, a 
receptor density of 105 copies of HER-2 receptors per cell was 
necessary to improve the therapeutic efficacy of anti-HER-2-
targeted liposomal DOX relative to its non-targeted counter part 
[98]. In vitro and in vivo comparisons have shown that the 
intracellular concentration of drug is much higher when the drug is 
released from NPs in the cytoplasm after internalization [6, 99] as 
P-gp cannot remove NPs that have entered the cells via endocytosis 
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[100, 101]. The selection of the targeting ligands should be based 
on its propensity to be internalized via receptor-mediated 
endocytosis (RME) [11, 100, 102, 103] (Fig. 1B), in this way 
increasing the therapeutic effect and overcoming the possibility of 
being extruded by the multi-drug resistance (MDR)-encoded P-gp 
[101]. The fact that some antibodies can provide NPs with the 
ability to be internalized makes the MAb-NP active targeting an 
alternative route for overcoming MDR. Direct experimental proof 
has been obtained by Sapra et al. [99] for liposomal drugs targeted 
against internalizing epitopes (e.g., CD19) compared with those 
targeted against non-internalizing epitopes (e.g., CD20). 
Administration of single intravenous doses into human B-
lymphoma (Namalwa) cells of DOX-loaded anti-CD19-targeted Ls 
resulted in a survival time of 45.6 days against 34.3 and 28.6 days 
obtained for the DOX-loaded anti-CD20-targeted L and the non-
targeted L formulations, respectively. This observation was 
attributed to the rapidly internalization of anti-CD19-targeted Ls, 
which allow delivering higher concentrations of drugs into the cell 
interior due to the breakdown of the drug-L package by lysosomal 
and endosomal enzymes, whereas those targeted with anti-CD20 
were not internalized [104]. 
The antibody or the antibody fragment can be conjugated to 
NPs by adsorption, by direct covalent linkage between the surface 
of the NP and the antibody, or by using adapter molecules such as 
streptavidin and biotin. The coupling method must be efficient, 
produce a stable association, allow control of the amount of 
antibody that is immobilized, and assure that the activity of the 
antibody is preserved. Covalent coupling presents a clear advantage 
compared to physical adsorption as the linkage prevents the 
competitive displacement of the adsorbed antibodies by blood 
components. The covalent attachment of the antibody would 
involve the Fc region, leaving the antigen-binding site Fab region 
oriented to the medium to preserve its full function. For direct 
coupling of antibodies on NP surface, amines and carboxylic acids, 
the most common groups present on NP surface, can be used for 
reaction with ligands. Various strategies to couple antibodies to 
NPs are represented on Fig. (3). Common conjugation methods are 
based on the reaction among carboxylic groups in the particle and 
primary amine groups in the antibody or antibody fragment in the 
presence of 1-ethyl-3 (3-dimethylaminopropyl) carbodiimide 
(EDC) and N-hydroxysuccinimide (NHS) to yield a stable amide 
bound [105]. Alternatively, amine groups on the surface of particles 
can be linked to sulfhydryl groups located at known sites away 
from the antigen binding sites in antibodies to create a stable 
thioether linkage after being modified through maleimide chemistry 
[106]. This method is preferred as in the first method the lack of 
specificity in the site of conjugation may affect antibody activity 
[107]. Moreover, during conjugation, the NHS-based reagents 
converted positively charged lysines into neutral groups, leading to 
a probable loss of recognizing activity[108]. 
Linkage strategy using avidin/streptavidin (SA)-biotin 
technology can also be used. It involves binding between avidin and 
biotin with a non-covalent nature however with an extremely high 
affinity and dissociation halftime [109]. SA or avidin must be 
introduced into the ligand structure after activation with N-
maleimidobenzoyl-NHS and reaction with sulfhydryl groups in the 
antibody, leading to the formation of a thioether bond [110]. In 
parallel, biotinylated nanocarriers must be prepared to react with 
SA/avidin-conjugated ligands. Another approach concern ligand 
biotinylation using NHS-PEG-biotin to insert biotin molecules on 
protein-bearing primary amine groups [111]. Gelatine and human 























Fig. (3). Strategies of coupling antibodies to NPs: reaction among carboxylic groups on the surface of particles and primary amine groups in the antibody in 
the presence of EDC and NHS to yield a stable amide bound (up); reaction among aldehyde groups on the surface of particles and primary amine groups in the 
antibody (middle); reaction among amine groups on the surface of particles and sulfhydryl groups in the antibody to create a stable thioether linkage after 
being modified through maleimide chemistry (bottom). 
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covalent attachment of the biotin-binding protein NeutrAvidinTM 
enabling the binding of biotinylated anti-HER-2 antibodies, 
showing intracellular specific cell targeting [112] . This group also 
described the selective targeting of the same NPs conjugated to 
antibodies specific for the CD3 antigen on CD3-positive human T-
cell leukaemia cells and primary T-lymphocytes [113]. It may be 
advantageous to attach an antibody to the distal tip of a PEG 
molecule rather than conjugate the antibody to the surface of a NP 
therefore avoiding steric hindrances for antibody-target interaction 
that PEG-coating NPs can create as observed in a PEG-conjugated 
L [114, 115]. Thus the PEG-molecule can be used as a spacer 
allowing the antibody to extend away from the NP surface. This 
approach has been used in vivo to target Ls to cells in tissue culture 
[116-118], and to lung [119] or brain [120]. Furthermore, functional 
groups on NP surface allow chemical conjugation to multiple 
diagnostic (i.e., optical, radioisotopic, or magnetic) and therapeutic 
agents, thus making possible to design and develop multifunctional 
NPs (Fig. 1a) that could be used to simultaneously imaging and 
treatment. Recent advances have led to bioaffinity NP probes for 
molecular and cellular imaging, targeted nanoparticulate drugs for 
cancer therapy, and integrated nanodevices for early cancer 
detection and screening [121]. These developments raise exciting 
opportunities. 
5. THERAPEUTIC APPLICATIONS OF ANTIBODY-CONJ-
UGATED NANOPARTICLES  
Some examples of the major MAb-based active targeting 
strategies for NP systems in therapy are reported below organized 
in: cancer treatment, brain targeting, inflammatory diseases, 
infectious diseases, and other applications such as thrombosis. 
Examples of antibody conjugated NP-based therapeutics in in vivo 
studies and in clinical trials are listed in Table 1. 
5.1. Tumour Therapy 
Cancer is a leading cause of death worldwide and accounted for 
7.6 million deaths (around 13 % of all deaths) in 2008. Deaths from 
cancer in the world are projected to continue rising, with an 
estimated 9 million people dying in 2015 and 11.4 million dying in 
2030 according to the World Health Organization [156]. 
Chemotherapeutic agents have widely been used in oncology for 
the past 25 years but they generally exhibit a short plasma half-life 
due to a rapid clearance and rapid biodegradation, which allied to a 
poor specificity determine the use of highly toxic doses that cause 
severe toxic effects. In addition, cancer is often diagnosed and 
treated too late, when the cancer cells have already invaded and 
metastasized into other parts of the body. More than 60 % of 
patients with breast, lung, colon, prostate, and ovarian cancer have 
hidden or overt metastatic colonies [121]. Therefore, the 
development of nanoscale delivery vehicles for targeted delivery of 
anticancer drugs to tumour cells/tissues can improve the therapeutic 
index of drugs and is likely one of the most exciting and clinically 
important application of cancer nanotechnology. Cell or tissue 
specific receptor/antigens can provide a useful target for cancer 
treatment [157]. Scientific investigations have identified cancer cell 
specific markers with unique phenotypes that can be exploited to 
target tumours. Primary tumours as well as metastatic tumours 
generally overexpress certain antigens on their surfaces [like HER-
2 in breast cancer, endothelial growth factor receptor (EGFR) in 
lymphoma cancer, etc.]. The ideal antigen should be expressed on 
all tumour cells but not expressed on critical host cells [158], 
should have no mutation or variation, and should be required for a 
critical cellular function [159]. Therefore, MAbs specific to 
particular tumour antigens can provide a good platform for 
conjugated NP targeting with high affinity and specificity as long as 
the particular antigens can be identified with confidence and are not 
expressed in significant quantities anywhere else in the body. 
Active tumour targeting is typically achieved by both local and 
systemic administration of MAb conjugated NPs. In the case of 
local delivery, particularly useful for primary tumours that have not 
yet metastasized, the cytotoxic drug encapsulated in the NP can be 
delivered directly to cancer cells while minimizing harmful toxicity 
to non-cancerous cells adjacent. For some tumours, such as lung 
cancers, that are difficult to access and for metastatic cancers, the 
location, abundance, and size of tumour metastasis within the body 
limits its visualization or accessibility thus requiring a systemic 
administration [55].  
Antibody-based therapy of human cancers has led to several 
remarkable outcomes, particularly in the therapy of breast cancer 
and lymphoma. Many solid tumours have proven less responsive, 
due in part to difficulties in the tumour-selective delivery of 
antibodies and potential cytolytic efectors. Moreover, NPs have the 
ability to accumulate in cells without being recognized by the P-gp, 
one of the main mediators of MDR, resulting in an increase in the 
intracellular concentration of drugs. Several studies concerning the 
development of antibody-conjugated NPs for cancer therapy have 
been performed and are reported in literature including in several 
reviews [2, 5, 6, 47, 102, 107, 121, 158, 160-169]. However, at 
present, there is only one formulation under clinical trial, MCC-
465, an IL-encapsulated DOX fabricated by Mitsubishi Pharma 
Corporation (Osaka, Japan) and no commercial formulation. In this 
formulation, the L is tagged with PEG and the F(ab′)2 fragment of 
HuMAb goat anti-human GAH, which positively reacts to > 90 % 
of cancerous stomach tissues but negatively to all normal tissues. In 
preclinical studies, the antitumour efficacy of MCC-465 was 
compared with those of free DOX or DOX-incorporated PEG Ls 
with an MKN-45 human gastric cancer xenograft model. A tumour 
weight of 8 mg, 18 mg, and 22 mg was obtained after three 
intravenous injections with 3.0 mg/Kg in terms of DOX, into nude 
mice for DOX-IL, DOX-L, and DOX, respectively. The result 
showed that DOX-IL activity was significantly greater than that of 
DOX or DOX-L [133, 134]. 
In this review, the current MAb-conjugated NPs under study for 
cancer targeting have been organized according to particular 
characteristics found in tumour development (neovasculature of 
angiogenesis and uncontrolled cell growth) and cell/organ tumour 
targeting. There is a large overlap between these divisions as the 
targeting of cell/organ tumours involves targets specific to the type 
of cancer but also many of the targets found in angiogenesis and 
uncontrolled cell proliferation. 
5.1.1. Targeting Through Angiogenesis and Uncontrolled Cell 
Proliferation 
5.1.1.1. Tumour Development 
Cancer is characterized by an uncontrolled growth of a group of 
cells that demands a higher amount of nutrients than healthy cells. 
Tumours cannot grow beyond a certain size, generally 1-2 mm3 
[158, 170, 171] due to a lack of oxygen and other essential 
nutrients. To growth beyond this size the formation of blood vessels 
is required to provide the necessary nutrients. The exact molecular 
mechanisms that initiate angiogenesis at a tumour site are not 
known and have been the subject of intense research. The rapid 
vascularization necessary to provide fast-growing cancers can 
create a defective vascular architecture which, coupled with a 
dysfunctional lymphatic drainage, causes an enhanced permeation 
relative to normal tissue and a fluid retention effect in the tumour 
interstitial space (EPR effect) [158, 172, 173] which can facilitate 
an extravasation of NPs out of tumour microvasculature (passive 
targeting) leading to an accumulation into the tumour interstitium 
[174]. The concentration of PNP and macromolecular assemblies 
found in tumour tissues can be up to 100-fold or greater than those 
in normal tissue [175, 176]. 
Since the development of new blood vessels is essential for 
tumour grow, an attractive antitumour strategy is to exploit the 
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Table 1. Antibody-Conjugated Nanoparticles-Based Therapeutics in In Vivo Studies and in Clinical Trials 
 
Composition Monoclonal Antibody Target Marker Indication Status Ref. 
Liposomes 
PEG-L-DOX Fab’ fragments of antibody 
against MT1-MMP 
HT1080 cells, overexpressing 
MT1-MMP 
Tumour angiogenic vessels In vivo [122] 
L-DOX MAb anti-HER2 HER2 Breast cancer In vivo [98, 123] 
L-DOX  anti-β1 Fab’ β1 integrin-positive lung tumour 
cells 
Lung carcer In vivo [124] 
PEG-L-DOX MAb 2C5 Tumour cell surface-bound 
nucleosomes) 
Lewis lung carcinoma; colon cancer; breast 
adenocarcinoma; prostate cancer 
In vivo [125, 
126] 
L-anti-HER-2-siRNA scFv fragment anti-TfR TfR Pancreas cancer In vivo [127] 
PEG-L-DOX  MAb 2C5 Tumour surface Prostate cancer In vivo [126] 
L-DOX; posome-
vincristine 
MAb anti-CD19   B-cell lymphoma B-cell lymphoma In vivo [128] 
L-DOX MAb anti-CD19  B-cell receptor B-cell lymphoma (blood cancer) In vivo [99, 104, 
129, 130] 
L-DOX MAb HD37 CD19-expressing Raji cells B-cell malignancies In vivo [131] 
PEG-L-DOX MAb HB22.7  
(anti-CD22) 
CD22-expressing Raji cells Non- Hodgkin’s lymphoma In vivo [132] 
PEG-L-DOX 
MCC465 
Human MAb GAH B37 cells Stomach cancer; colorectal cancer Phase 1 [133, 
134] 
L-ferentinide Anti-GD2 Disialoganglioside (GD(2)) at the 
cell surface 
Neuroblastoma and melanoma In vivo [135] 
L-DOX Anti-GD2 Disialoganglioside (GD(2)) at the 
cell surface 
Neuroblastoma In vivo [136] 
PEG-L-DOX MAb 2C5 U-87 MG tumour cells Brain tumours In vivo [137] 
L-daunomycin MAb OX26  RBE4 brain capillary endothelial 
cells 
Brain targeting In vivo [138] 
L-boron compounds Cetuximab  EGFR Glioma cells 
brain targeting 
In vivo [139] 
L-boron compounds MAb anti-EGFR EGFR Glioma cells 
brain targeting 
In vivo [140] 
L- dexamethasone Anti-E-selectin E-selectin Skin inflammation 
glomerular renal Inflammation 
In vivo [141, 
142] 
L-indinavir Anti-HLA-DR Lymphoid cells Lymph nodes 
HIV 
In vivo [143] 
PEG-L Anti-HLA-DR Fab’ fragment HLA-DR Lymphoid organs: deep cortex of lymph 
nodes; white pulp of the spleen 
(HIV) 
In vivo [144] 
L-chloroquine MAb F10 Erythrocytes Infected erythrocytes: 
malaria 
In vivo [145] 
L-chloroquine Anti-erythrocyte F(ab’)2 Erythrocytes Infected erythrocytes: 
malaria 
In vivo [146, 
147] 
Polymeric Nanoparticles 
PLGA-PE38KDEL Anti-HER2  HER-2 Breast cancer In vivo [148] 
PLGA Anti-ICAM ICAM Lung cancer In vivo [149] 
poly(lactic acid-co-l-
lysine) 
EGFR MAb  EGFR positive cancer cells HCC In vivo [150] 
PLA- paclitaxel 
PEG-PLA- paclitaxel 
Anti-HER2 HER-2 Prostate cancer In vivo [151] 
Dextran-coated 
polymerized L 
Anti-Flk-1 MAb VEGFR-2 (Flk-1) Melanoma In vivo [152] 
Chitosan-PEG-caspase 
inhibitor 
MAb OX26 TfR Brain cancer In vivo [153] 
PEG-PLGA Anti-ICAM-1; anti-VCAM-1; 
anti-E-selectin; anti-P-selectin 
ICAM-1; VCAM-1; E-selectin; P-
selectin 
Inflamed endothelium In vivo [154] 
Polymeric Micelles 
PLGA-PEG-DOX HAb18 F(ab’)2 Hepatocellular carcinoma Liver cancer In vivo [155] 
 
biochemical differences between the vasculature of the tumour and 
the normal tissues, and aim at the tumour vasculature for 
therapeutic treatment with MAb-bearing long-circulating particles. 
Targeting the tumour vasculature provides an approach to 
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circumvent the mechanical barriers that impede homogeneous 
distribution of drugs within the tumour tissue. Other advantages of 
targeting the tumour vasculature rather than the tumour cells 
themselves include a potentiating effect, because one blood vessel 
nourishes hundreds of tumour cells, and a reduced probability that 
drug resistance will develop, because endothelial cells have a lower 
mutation rate than cancer cells [177]. As more information is 
known about the molecular mechanisms of angiogenesis new 
therapeutic targets can emerge. Molecules involved in proliferation 
and invasion are generally overexpressed on the surface of tumour 
cells and include proteins involved in cell-cell or cell-matrix 
interactions [e.g., E-selectin, vascular cell adhesion molecule-1 
(VCAM-1), and the αvβ3 integrin complex] and growth factor 
receptors [EGFR, vascular endothelial growth factor receptor 
(VEGFR), and folate receptor] [9] which means that they are 
exposed at the cell surface, can be recognized by specific carriers, 
and can internalize them making these molecules potential 
pharmacological targets for anti-angiogenic therapy.  
5.1.1.2. Targeting Through Angiogenesis  
The most established angiogenic targets used by nanopar-
ticulate systems for therapeutic benefit include the VEGFRs, αvβ3 
integrin, VCAM-1, and matrix metalloproteinase (MMPs) [162]. 
5.1.1.2.1. Vascular Endothelial Growth Factor Receptor (VEGFR) 
In situ hybridization studies demonstrate VEGF mRNA 
expression in many human tumours. These include lung, breast, 
gastrointestinal tract, renal, and ovarian carcinomas. However, the 
expression of VEGF appears to be variable, not only among 
different tumour types but also within the same tumour [178]. 
VEGFR is considered the most relevant inducer of tumour 
angiogenesis for its induction of the VEGF receptor signalling 
cascade. The VEGF receptor of interest for most active targeting 
systems is VEGFR-2 as it is associated with the binding of VEGF, 
initiating the signalling cascade for angiogenesis [179], and is 
highly expressed on endothelial cells in tumour neovasculature. 
Apart from angiogenesis, a small number of melanoma and 
leukaemia cell lines express VEGFR-2 in non-endothelial cells 
[180, 181]. Both VEGF and VEGFR-2 are seen as promising 
targets for NP systems with the goal to interfere with 
neoangiogenesis by: 1) targeting VEGFR-2 to decrease VEGF 
binding; and, 2) targeting VEGF to inhibit ligand binding to 
VEGFR-2 [152, 182]. 
Anti-VEGFR-2 MAb-labeled polymeric Ls radiolabeled with 
90Y (anti-VEGFR-2 MAb-L-90Y) were produced by Li et al. [152] 
to target VEGFR-2 in a mouse melanoma model. A significant 
tumour growth delay was obtained using anti-VEGFR-2 MAb-L-
90Y treatment compared to untreated tumours as well as tumours 
treated with anti-VEGFR-2 MAbs alone or with 90Y-labeled anti-
VEGFR-2 MAb. The treatment with anti-VEGFR-2 MAb-L-90Y 
also showed a marked decrease in vessel density which was 
associated with a high level of apoptotic death in these tumours. A 
method to target VEGF used anti-VEGF MAb PLA NPs loaded 
with 5-fluorouracil that show an increase in the tumour inhibitory 
rate of the drug. These particles show to induce apoptosis by 
inhibiting tumour angiogenesis with fewer side effects, and 
therefore enhanced therapeutic effect in human gastric carcinoma 
xenografts of nude mice [183]. Bevacizumab (Avastin®), approved 
in 2004, is a recombinant humanized MAb that binds to VEGF. 
Clinical trials of bevacizumab have been carried out for the past 
few years without evidence of significant clinical activity as a 
single agent. However, more recent studies have suggested that 
combining bevacizumab with chemotherapy can be effective in 
patients with non small cell lung cancer, advanced breast cancer, 
and colon cancer. 
5.1.1.2.2. αvβ3 Integrins 
Integrins are cell adhesion receptors that bind to the 
extracellular matrix (ECM) proteins harboring the RGD (arginine-
glycine-aspartic acid) sequence and cell surface ligands. Their role 
is to transmit and detect changes from the extracellular matrix to 
intracellular signalling and thus regulate tumour growth, 
angiogenesis, proliferation, apoptosis, or metastasis [184]. Most 
tissues and cell types are characterized by low αvβ3 integrin levels 
or absence of αvβ3 integrin expression. However, it is overexpressed 
on neovascular endothelial cells and is important in the calcium-
dependent signalling pathway leading to endothelial cell migration 
[185]. Furthermore, in some cancers such as breast cancer or 
melanoma, αvβ3 expression appears to correlate with the 
aggressiveness of the disease [186, 187]. Therefore, selective 
targeting of αvβ3 integrin is a novel antiangiogenesis strategy for the 
treatment of solid tumours. Antibodies and peptides that block the 
function of αvβ3 and αvβ5 integrins have been shown to inhibit 
neovascularization in several in vivo models of pathological 
angiogenesis in mice [186, 188]. HSA NPs containing DOX were 
conjugated with a MAb directed against αv integrins (DI17E6) using 
a heterobifunctional NHS-PEG-maleimid linker after MAb 
thiolation [189]. The produced NPs have shown the ability to 
specific target αvβ3 integrin positive melanoma cells and an 
increased cytotoxic activity in αvβ3 positive melanoma cells than the 
free drug. The half maximal inhibitory concentration (IC50) 
obtained for NP-DOX-DI17E6 was 8.0 ng/mL, while for NP-DOX 
and free DOX was 30.8 ng/mL and 57.5 ng/mL, respectively. 
5.1.1.2.3. Vascular Cell Adhesion Molecule (VCAM) 
VCAM-1, an immunoglobulin like transmembrane glycopro-
tein, that is expressed on the surface of endothelial cells during 
inflammation and cancer and promotes cell-to-cell adhesion [190], 
is an optimal target as it is absent in normal human vasculature but 
readily inducible by angiogenesis. In cancer, increased VCAM-1 
expression is linked to leukaemias and lymphomas, such as 
Hodgkin’s disease and B-cell lymphocytic leukaemia, lung and 
breast cancer, melanomas, renal cell carcinoma, gastric cancer, and 
nephroblastoma [177]. The possibility of using antibodies to target 
VCAM-1 was checked using magnetooptical NPs conjugated to 
anti-VCAM-1 to specifically target murine heart endothelial cells 
expressing high levels of VCAM-1[191]. 
The first morphological evidence for selective in vivo targeting 
of tumour vessels using ILs were performed by Gosk et al. [192] 
that used PEG-modified ILs directed against VCAM-1. In vitro, 
anti-VCAM-1 Ls displayed specific binding to activated endothelial 
cells under static conditions, as well as under simulated blood flow 
conditions. The in vivo targeting of ILs was analyzed in mice 
bearing human Colon 677 tumour xenografts 30 min and 24 h post 
intravenous injection. Fluorescence microscopy studies revealed 
that VCAM-1 targeted ILs accumulated in tumour vessels with 
increasing intensities from 30 min to 24 h, while control ILs 
accumulated in the tumour tissue by passive diffusion [192]. 
5.1.1.2.4. Matrix Metalloproteinases (MMP) 
The main MMP target for NP systems has been the membrane 
type 1-matrix metalloproteinase (MT1-MMP). MT1-MMP is a 
membrane-anchored endopeptidase that is involved in the 
degradation of various extracellular matrix components, endothelial 
cell invasion and migration, and formation of capillary tubes [193]. 
It is located on angiogenic endothelium but not on the endothelial 
cells of pre-existing blood vessels [194]. MT1-MMP plays an 
important role in angiogenesis and is expressed on angiogenic 
endothelium cells as well on certain types of tumour cells, including 
malignancies of lung, gastric, colon, breast, cervical carcinomas, 
gliomas [122], and melanomas [122, 195, 196]. 
In a study performed by Hatakeyama et al., modification of 
PEG-Ls containing DOX with Fab fragments of anti-human MT1-
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MMP MAb significantly enhanced cellular uptake into the HT1080 
cells, which highly express MT1-MMP, compared with the non-
targeted Ls suggesting that MT1-MMP antibody (Fab’s) is a potent 
targeting ligand for the MT1-MMP expressed cells. In vivo 
systemic administration of targeted-Ls into the tumour-bearing 
mice showed significant suppression of tumour growth compared to 
the non-targeted Ls. When DOX-Ls was administered, tumour 
volume was decreased in only 1 out of 6 mice at 12 and three of 
six mice died up to 12 day. In contrast, in the case of DOX-IL-
anti-MT1-MMP(Fab’s), tumour volume decreased efficiently in 
half of mice at 12 days and no mouse died. Tumour accumulation 
for targeted and non-targeted Ls were comparable, suggesting that 
the enhanced antitumour activity of the targeted formulation 
resulted from acceleration of cellular uptake of Ls owing to the 
incorporated antibody after extravasation from capillaries in tumour 
[122]. 
5.1.1.3. Targeting Through Uncontrolled Cell Proliferation  
The main cell proliferation targets explored by NP systems for 
therapeutic benefit include the human epidermal receptors (HER), 
transferrin receptors (TfR) and folate receptors, which are often 
overexpressed on tumour cells. The conjugation of antibodies 
against folate receptors has been suggested in literature but there is 
no published work concerning this thematic. The most common 
way to target folate receptors has been the conjugation of folate to 
NPs but is outside the scope of this article. 
5.1.1.3.1. Human Epidermal Receptor (HER) 
The HER family offers two highly upregulated targets on 
tumour cell surfaces known to mediate a cell signalling pathway for 
growth and proliferation in response to the binding of the growth 
factor ligand: the EGFR and the human epidermal receptor-2 (HER-
2). As a result, EGFR and HER-2 are the most heavily researched 
for cancer therapeutic applications. The EGFR is expressed in a 
wide variety of solid tumours. It has been demonstrated that the 
EGFR-associated signalling pathway plays an important role in 
carcinogenesis and cancer progression. Clinical studies using MAb 
blockade and EGFR tyrosine kinase inhibitors have suggested that 
EGFR blockade is a well-tolerated and effective treatment strategy 
[197]. 
A current cancer treatment is the MAb Cetuximab, approved in 
2004 by FDA, which targets EGFR and is usually administered in a 
combinatory therapy in head and neck cancers. ILs with conjugated 
Fab’ fragments of Cetuximab MAb were synthesized for targeted 
delivery of boron compounds to EGFR-positive glioma cells 
(F98EGFR) for neutron capture therapy. Much greater (8-fold) 
cellular uptake of boron was obtained using cetuximab-ILs in 
EGFR-positive cells compared with non-targeted human IgG-ILs 
[139]. Poly(lactic acid-co-L-lysine) NPs conjugated to a EGFR 
MAb have shown to bind to and be uptaken by hepatocellular 
carcinoma cells effectively. They also show an effective tumour 
targeting in vivo in a xenograft mouse model [150]. 
HER-2 also plays a significant role in the pathogenesis of many 
different types of cancers, and offers an attractive target for MAb-
based therapeutic strategies. The use of Trastuzumab [198] as a 
targeting moiety offers an attractive strategy for MAb conjugated 
NPs. Several studies demonstrated that PNP functionalized with 
anti-HER-2 MAb can specifically bind and deliver drugs or toxins 
to breast carcinoma cells and prostate cancer cells which 
overexpress HER [199-203]. PLGA/montmorillonite NPs 
containing paclitaxel have been decorated with the HER-2 
Trastuzumab antibody for targeted breast cancer chemotherapy. In 
vitro studies in Caco-2 colon adenocarcinoma cells and in SK-BR-3 
breast cancer cells show that the antibody-conjugated NPs achieved 
significantly higher cellular uptake than the pure colloid. Moreover, 
in vitro cytotoxicity on SK-BR-3 cells showed that the anticancer 
action of the drug formulated in the conjugated NPs was 12.7 times 
higher than that of the bare NPs, and 13.1 times higher than free 
Taxol® [204]. 
Liu et al. has performed a study on the quantitative control of 
targeting effect of docetaxel-loaded NPs of a PLGA-PEG/PLGA 
copolymer blend conjugated to HER-2. Comparing with a pre-
conjugation strategy, the post-conjugation strategy in which the 
ligand is conjugated onto the DOX containing PLGA-PEG NPs 
already prepared provides more efficient use of the ligand and 
protects its bioactivity in the NP preparation process, thus resulting 
in much better performance in drug targeting, which was assessed 
in vitro with SK-BR-3 breast cancer cells of HER-2 receptor 
overexpression and MCF7 breast cancer cells of HER-2 receptors 
moderate expression. He also found a linear relation between the 
copolymer blend ratio of the NP matrix and the ligand density and 
that the amount of PNP endocytosed by SK-BR-3 cells was almost 
proportionally increased to the surface density of the ligand. This 
shows indeed an experimental evidence for the proposed copolymer 
blend strategy for precision engineering of the NPs [205]. 
The biodistribution and intracellular distribution of long-
circulating ILs targeted to HER-2 prepared by conjugation of anti-
HER-2 MAb fragments (Fab’ or single chain Fv) to PEGylated Ls 
was studied by Kirpotin et al. [123]. They found that MAb 
fragment conjugation did not affect the biodistribution or long-
circulating properties of intravenously administered Ls nor increase 
the tumour localization of ILs, as both targeted and non-targeted Ls 
achieved similarly high levels (7-8 % injected dose/g tumour tissue) 
of tumour tissue accumulation in HER-2-overexpressing breast 
cancer xenografts (BT-474). However, studies using colloidal gold-
labelled Ls showed the accumulation of anti-HER-2 ILs within 
cancer cells, whereas matched non-targeted Ls were located 
predominantly in extracellular stroma or within macrophages. A 
similar pattern of stromal accumulation without cancer cell 
internalization was observed for anti-HER-2 ILs in non-HER-2 
overexpressing breast cancer xenografts (MCF-7). Flow cytometry 
of disaggregated tumours post treatment with either Ls or ILs 
showed up to 6-fold greater intracellular uptake in cancer cells due 
to targeting. The results demonstrated that, in contrast to non-
targeted Ls, anti-HER-2 ILs achieved intracellular drug delivery via 
MAb-mediated endocytosis, and this, rather than increased uptake 
in tumour tissue, was correlated with superior antitumour activity. 
A very interesting study of the tracking of NP labelled with the 
MAb anti-HER-2 after injection into mice with HER-2-
overexpressing breast cancer was reported by Tada et al. using 
quantum dots [97]. They successfully identified six processes of 
delivery: initially in the circulation within a blood vessel, during 
extravasation, in the extracelullar region, binding to HER-2 on the 
cell membrane, moving from the cell membrane to the perinuclear 
region, and in the perinuclear region. The six processes were 
quantitatively analyzed to understand the rate-limiting constraints 
on quantum dot-antibody delivery. They found that the movement 
of the complexes at each stage was “stop-and-go”. 
5.1.1.3.2. Transferrin 
Transferrin (Tf) is an iron-binding blood plasma glycoprotein 
that is involved in the transport of iron to proliferating cells. After 
binding to TfRs, it is endocytosed into acidic compartments where 
the iron dissociates. Due to the increased requirement of iron during 
cell proliferation, an increase number of TfRs is present on 
metastatic cells compared to normal healthy cells which make them 
of particular interest to act as targets for cancer therapeutics [206]. 
The conjugation of Tf to NPs is the most common way to target 
TfRs however is outside the scope of this article. 
Single-chain antibody Fv fragment (scFv) against TfR has been 
conjugated to a cationic L-DNA complex to target tumour cells 
[207]. This scFv-IL can deliver the complexed gene systemically to 
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tumours in vivo, where it is efficiently expressed. Barth et al. [208] 
describes the design and synthesis of fluorescent calcium 
phosphosilicate nanocomposite particles (CPNP) bioconjugated to 
anti-CD71 antibody (an anti-TfR antibody) via an avidin-biotin 
coupling strategy and their targeting ability to TfRs, which are 
highly expressed on breast cancer cells, in an in vivo model of 
breast cancer. The study shows that, 96 h following tail vein 
injection, anti-CD71-avidin-CPNP was more effective at targeting 
the tumour than the passively accumulating untargeted-CPNP and 
transferrin-conjugated CPNP based on the relative fluorescence 
intensity. This behaviour was attributed to the saturation of TfRs 
with Tf which turns them unable to bind to the Tf-CPNP and 
explained the success of the anti-CD71-avidin-CPNP, which 
recognize an epitope separate from the ligand-binding site on the 
TfR. However, the effective targeting was not limited to the 
tumours, but also to the spleen, which is rich in diversity of 
hematopoietic cells and to the stomach. Overall, these findings 
showed that the anti-CD71-avidin-CPNP were effective and 
selective in an in vivo model of breast cancer and have the potential 
to perform as a theranostic modality, simultaneously enhancing 
drug delivery, targeting, and imaging of breast cancer tumours. 
5.1.2. Tumour Cell Targeting 
According to the American Cancer Society cancer statistics for 
2011, cancers of the lung and bronchus, prostate, and colorectum in 
men, and cancers of the lung and bronchus, breast, and colorectum 
in women continue to be the most common causes of cancer death 
[209]. These 4 cancers account for almost half of the total cancer 
deaths among men and women. Tumour cell targeting involves 
many of the targets mentioned in the previous section: targeting 
through angiogenesis and uncontrolled cell proliferation. However, 
there are other targets that are specific to the type of cancer that are 
included in this Section as well as antibody-conjugated NP systems 
that have shown specific targeting upon in vivo administration. 
5.1.2.1. Breast Cancer 
At present, breast cancer is the most frequently diagnosed 
cancer and the leading cause of cancer death among females, 
accounting for 23 % of the total cancer cases and 14 % of the 
cancer deaths [209]. One of the most used strategies for targeted 
delivery to breast cancers uses the HER-2, a growth factor receptor 
found to be overexpressed in 20-30 % of human breast cancers 
[210], already mentioned in Section 5.1.1. 
Trastuzumab has been used as recognizing unit attached to NPs 
for breast cancer therapeutics. PLGA NP containing a model 
protein toxin (PE38KDEL) were covalently conjugated with Fab’ 
fragments of a humanized anti-HER-2 MAb by a two-step 
carbodiimide method to get PE38KDEL-loaded NP-anti-Fab’ 
bioconjugates (PE-PNP-anti-HER) [203]. The administration of PE-
PNP-anti-HER in mice previously inoculated with BT-474 cells 
showed that compared with PE-anti-HER, the antitumour activity of 
PE-PNP-anti-HER was markedly improved: the final mean tumour 
load was 36 ± 8 mm3 (0.3 mg/Kg) and 6 ± 2 mm3 (0.9mg/Kg), 
respectively. In addition, they were well tolerated in mice with a 
much higher MTD (maximally tolerated dose) than PE-anti-HER 
(2.92 mg/Kg vs. 0.92 mg/Kg), indicating that the systemic toxicity 
of PE38KDEL was dramatically reduced by PLGA encapsulation. 
Park et al. [98] produced DOX-loaded anti-HER-2 ILs that show 
marked therapeutic results in four different HER-2 overexpressing 
tumour xenograft models including growth inhibition, regression, 
and cures, and that were significantly superior to all other treatment 
conditions tested, including free DOX, non-targeted liposomal 
DOX, recombinant anti-HER-2 MAb trastuzumab, and combina-
tions of these other agents. An enhanced accumulation in tumours 
and an in vivo therapeutic activity was observed by Elbayoumi and 
Torchilin [126] after coupling the anticancer MAb 2C5 with 
nucleosome-restricted activity that can recognize the surface of 
various tumours but not normal cells to long-circulating Ls 
containing DOX. These results are presented in Fig. (4) for all the 
produced liposomal preparations showing the biodistribution (Fig 
4a), the whole body imaging of subcutaneous 4T1 tumour-bearing 
mice 4 h after the injection (Fig. 4c), and the therapeutic activity 
achieved expressed as tumour volumes (Fig. 4b) [126]. The final 
average tumour weight in animals with murine breast 
adenocarcinoma treated with MAb 2C5-DOX-Ls was only 0.3 g 
compared with 1 g in animals treated with non-specific UPC10-
modified DOX or original DOX, and 2 g in animals receiving only 
the buffer injections. 
5.1.2.2. Lung Cancer 
According to the Globocan programme from the World Health 
Organization, lung cancer accounted for 1.45 million of deaths and 
1.7 million new cancer cases in 2010 [211]. Bevacizumab 
(Avastin®), a humanized MAb that binds to VEGF was approved in 
2004 for treating non-small cell lung cancer, metastatic colorectal 
cancer, and metastatic breast cancer [178]. Present research in 
targeted therapeutics for lung cancer involves inhalable and 
injectable systems. Several studies performed show that the major 
obstacle, after intravenous injection, is to overcome the massive 
liver uptake therefore making difficult to achieve NP accumulation 
in the lungs [212]. The lack of ligands specific to lung cancer cells 
has limited lung targeting using NPs. Antibody-targeted therapies 
are beginning to offer a realistic alternative to palliative 
chemotherapy for many patients with advanced non-small cell lung 
cancer (NSCLC). Woodward et al. have studied the biodistribution 
of NPs linked to either a MAb to mouse lung thrombomodulin 
(MAb 201B) or a control antibody (MAb 33) and injected into 
groups of female mice using radioactive cadmium telluride/zinc 
sulfide (CdTe/Zn) systems for in vivo imaging. 1 h post-injection, 
the maximum lung accumulation for the group that received the 
MAb 201B-NPs was 437 ± 26 % ID/g tissue (a whole murine lung 
weighs ≈ 0.1 g) vs. 4 ± 0.9 % ID/g for the group that received the 
MAb 33-NPs. At 1 h, this represented a 100-fold increase in 
targeting efficacy vs. control [213]. Although toxicity reasons are 
likely to prevent CdTe/Zn systems from being used clinically, this 
system serves as a useful surrogate for answering questions about 
targeting efficacy. Debotton et al. has designed PLA NPs 
conjugated to a MAb (AMB8LK) that specifically recognizes H-
ferritin to target tumours overexpressing H-ferritin [151, 214]. 
AMB8LK has been shown to exhibit marked affinity for specific 
tumour organs such as pancreatic and lung (NSCLC) cancers. The 
AMB8LK immunoPNP showed significantly increased binding 
properties and increased uptake on human H-ferritin overexpressing 
cell lines (CAPAN-1 and A-549) compared to non-conjugated PNP. 
The immunoNPs containing paclitaxel palimitate also show an 
increased cytotoxicity presenting a 65 % cell survival when 
compared to 90 % obtained with a paclitaxel palimitate solution and 
blank paclitaxel palimitate PNP. The immunoNP were more 
effective than both controls, probably as a result of the extensive 
cell uptake of the immunoNP. 
Sugano et al. [124] produced DOX-loaded anti-b1 Fab’ ILs that 
show to be 30-fold more cytotoxic to β1 integrin-positive lung 
tumour cells than drug-loaded Ls without antibody, nonspecific 
Fab’ control ILs with drug or ILs without drug. The therapeutic 
efficacy of DOX-loaded ILs was also evaluated in a metastatic 
human lung tumour xenograft/severe combined immunodeficient 
mouse model. Treatment resulted in a significant suppression of 
tumour growth, prevented the metastatic spread of the tumour to the 
liver and adrenal glands and increased the median survival time of 
the tumour-bearing mice compared to mice treated with control 
formulations. Muzykantov and colleagues have shown that lung 
delivery can be significantly enhanced by immunotargeting the 
pulmonary endothelium with MAbs directed against intercellular 
adhesion molecule 1 (ICAM-1) [149, 215]. Although this 
immunoglobulin-like transmembrane endothelial adhesion 
molecule is constitutively expressed in the tissues of every organ, 
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favorable pharmacokinetics (a result of the high-flow, high-
capacity, and low-resistance nature of the pulmonary vasculature) 
ensure relatively high lung extraction of materials coupled to anti-
ICAM antibodies [216]. NP targeting ICAM-1 hold promise as a 
mean of delivering therapeutics to the pulmonary endothelium. (see 
examples in Section 5.4.). 
5.1.2.3. Liver Cancer 
Hepatocellular carcinoma (HCC) is the sixth most common 
tumour worldwide, but due to its poor prognosis, it ranks as the 
third most common cause of death from cancer [156]. The global 
incidence of HCC is greater than a million cases a year. General 
chemotherapy and radiotherapy offer somewhat unsatisfactory 
responsiveness, making new therapeutic strategies an immediate 
need to combat HCC. Targeted cancer therapy is promising to 
minimize the non-specific toxicity and to improve therapeutic 
efficiency compared to conventional chemotherapy. 
Kou et al. produced paclitaxel-loaded PLGA NPs coated with 
cationic SM5-1 single-chain antibody (SM5-1 scFv) which binds to 
a membrane protein specifically expressed on melanoma, HCC, and 
breast cancer cells [217]. The produced NPs were tested for their 
binding affinity and cytotoxicity in SM5-1 binding protein positive 
Ch-hep-3 cells, which is a human HCC cell line, and have 
significantly enhanced in vitro cytotoxicity as compared with non-
targeted paclitaxel-loaded PLGA NPs. Jin et al. reported on the 
development of targeted DOX-PLGA-PEG micelle decorated with 
a half-antibody (HAb) HAb18 F(ab′)2 (anti-HCC specific) for HCC 
chemotherapy [155]. The distribution profiles of targeted micelles 
in nude mice bearing HepG2 xenograft 2 h after intravenous 
administration showed that micelles were mainly distributed into 
the tumour and that a lower or invisible accumulation was observed 
in brain, heart, lung, liver, spleen, and kidney. Three days after the 
final administration, the inhibition rates of tumour (%) were 39.8, 
50.2, and 63.9 % for free DOX, non-targeted, and targeted micelles, 
respectively. The significantly lower accumulation detected in the 
heart indicated that the cardiac toxicity of DOX might be 
substantially reduced by the formulation of micelles. This result is 
encouraging because the cardiac toxicity is one of the most 
significant side effects of DOX chemotherapies. 
5.1.2.4. Pancreas Cancer 
Pancreatic cancer has the worst mortality rate and the lowest 
overall survival in all cancers. Only about 10 % of patients are 
presented with resectable disease and are suitable for potentially 
curative surgery [218]. Chemotherapy is still the only option in 
metastatic pancreatic cancer treatment although current regimens 
are met with little success as poor tumour vascularization 
significantly limits the delivery of oncological drugs. At most of the 
times, chemotherapy is purely palliative with minimal impact on 
survival. Therefore, developing novel, specific, tumour-targeted 
drug delivery systems is urgently needed for this terrible disease. 
Immunotherapy, especially antibody therapy, has shown great 
promise in pancreatic cancer treatment. Many studies suggest that 
EGF and VEGF pathways are activated in a large amount of human 
pancreatic cancers. EGFR and VEGF expressions are associated 
with the prognosis of pancreatic cancer [219]. It has been shown 
that anti-EGFR MAbs including cetuximab and matuzumab inhibit 
the tumour growth and angiogenesis, and when combined with 
chemotherapeutics such as gemcitabine led to significant increase 
in tumour growth inhibition. Also bevacizumab has demonstrated 
the benefit of being used in combination with previously failed 
chemotherapy for pancreatic cancer [220]. Mesothelin is a tumour 
differentiation antigen that is highly expressed in human malignant 
tumours including pancreatic cancer [221]. Therefore, the use of 
anti-mesothelin antibodies as targeting moieties attached to NPs can 






















Fig. (4). (a) Tumour accumulation of the liposomal preparation. (b) Therapeutic activity, expressed as tumour volumes, of 2C5-Doxil® against control 
preparations in 4T1-mice. Arrows, treatment schedule, 2 mg/Kg every 5 d (n = 8- 10). (c) Whole body γ-imaging of subcutaneous 4T1 tumour-bearing mice 4 
h after the injection of 111In-labeled Ls: control Doxil®-mimicking Ls (A), non-specific UPC10-Doxil®-mimicking Ls (B), and MAb 2C5-Doxil®-mimicking Ls 
(C). Circles show tumor locations. Adapted with permission from Ref. [126]. Copyright AACR (2009). 
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genes have been indicated as potential targets for the specific 
delivery in pancreatic cancer including urokinase plasminogen 
activator receptor, Tf, HER-2, CA125 (a cell surface associated 
glycosylated mucin protein, also known as MUC16), and stem cell 
markers such as the epithelial cell adhesion molecule (EpCAM), 
CD44, and CD133 highly expressed in more than 50 % of 
pancreatic cancers. Studies performed have shown that targeting of 
these receptors using specific antibodies inhibits pancreatic cancer 
growth [219]. ILs composed of siRNA encapsulated by a cationic 
Ls, the surface of which is decorated with an anti-TfR single-chain 
antibody fragment, have been developed to deliver anti-HER-2 
siRNA preferentially to tumour cells and show that can sensitize 
human tumour cells to chemotherapeutics, silence the target gene 
and affect its downstream pathway components in vivo, and 
significantly inhibit tumour growth in a pancreatic cancer model 
[127]. The inclusion of a pH sensitive histidine-lysine peptide 
(HoKC) in the complex (scL-HoKC) enhances endosomal release 
resulting in increased effect. The advantage of using these 
immunoNPs is that it not only benefits pancreatic cancer treatment 
but also can apply to other cancer with HER-2/neu overexpression. 
Thus, this complex has the potential to help translate the potent 
effects of siRNA into a clinically viable anticancer therapeutic. 
Hu et al. used an anti-carcinoembryonic antigen half antibody 
(HAb), because the carcinoembryonic antigen (CEA) is 
overexpressed in 90 % of pancreatic tumours [223], to synthesize 
HAb conjugated lipid-polymer hybrid NPs (HAb-NPs) and 
characterize their ligand conjugation yields, physicochemical 
properties, and targeting ability against pancreatic cancer cells. In 
addition, using paclitaxel as a model chemotherapy drug, they 
showed superior cytotoxicity of the targeted NPs against a human 
pancreatic cell line BxPC-3 in comparison with their non-targeted 
counterparts. The IC50 values of 251 nM and 526 nM were obtained 
for the HAb-NPs and non-targeted NPs, respectively, which 
translated to a more than 2-fold increase in therapeutic efficacy due 
to the anti-CEA HAb targeting [224]. At present, there are very few 
clinical trials using targeted drug delivery (using virus vector and 
magnetic beads) to treat pancreatic cancer and none using 
antibodies as targeting unit. 
5.1.2.5. Prostate Cancer 
Prostate cancer is the second most frequently diagnosed cancer 
and the sixth leading cause of cancer death in males, accounting for 
almost 100000 of the total new cancer cases [211]. In vivo 
inoculation of paclitaxel palmitate-loaded anti-HER-2 PEGylated 
PNP in mice elicited a significant antitumour activity in a 
metastatic prostate cancer model that overexpressed the HER-2 
receptor as compared to the paclitaxel palmitate solution and non-
targeted PNP [151]. Both non-targeted PNP and immunoPNP 
showed significantly increased plasma concentrations and plasma 
half-life values as compared to the values of paclitaxel palmitate 
solution in mice, although no significant difference between them. 
They also found that the immunoPNP concentrated much less in the 
liver and spleen than PNP. An enhanced accumulation in tumour 
and in vivo therapeutic activity was observed with MAb2C5-DOX-
Ls when tested against human prostate cancer in nude mice [126]. 
The final average tumour weight in animals treated with MAb2C5-
DOX-Ls was only 0.7 g compared with 1.7 g in animals treated 
with non-specific UPC10-modified DOX or plain DOX, and 3.3 g 
in animals receiving only the buffer injections. 
5.1.2.6. Colon Cancer 
Colorectal cancer is the third most malignant disorder, with 
over 1.2 million new cancer cases and 641000 deaths estimated to 
have occurred in 2010 [211]. Some examples of antibody-based 
targeted therapies for colorectal cancer already approved by the 
FDA include bevacizumab, cetuximab, and panitumumab (Amgen), 
a human antibody against EGFR produced in transgenic mice, 
approved in 2006 for the treatment of EGFR positive colorectal 
cancer that has seen disease progression despite prior treatment. 
These approvals signal the potential of antibody-targeted 
nanocarriers on colorectal cancer therapy simultaneously binding 
and inhibiting cancer pathways while delivering therapeutic 
payloads. Conjugates of DOX with linear and star-like 
hydroxypropyl methacrylamide polymers were functionalized with 
two different types of MAbs specific to the TfRs which are 
expressed in colorectal cancer cells [225], and showed significantly 
better therapeutic efficacy in vivo. Remarkably, star-like targeted 
conjugates delayed tumour growth significantly longer than linear 
targeted conjugates, stressing the importance of carrier design on 
the final results. An enhanced accumulation in tumour and in vivo 
therapeutic activity was observed with MAb2C5-DOX-Ls when 
tested against primary murine colon tumour in nude mice [126]. 
The final average tumour weight in animals treated with MAb2C5-
DOX-Ls was only 0.43 g compared with 1.7 g in animals treated 
with nonspecific UPC10-modified DOX or plain DOX, and 4.5 g in 
animals receiving only the buffer injections. PLGA PNP coated 
with conatumumab (AMG 655) death receptor 5 (DR5)-specific 
antibodies have shown to preferentially target DR5-expressing cells 
and to induce apoptosis via DR5, unlike free AMG 655 or non-
targeted control PNP in colorectal HCT116 cancer cells [226]. 
Also, DR5-targeted PNP encapsulating camptothecin are effectively 
targeted to the tumour cells, thereby producing enhanced cytotoxic 
effects through simultaneous drug delivery and apoptosis induction. 
5.1.2.7. Leukaemia 
Advances in chemotherapy, targeted therapy, and stem cell 
transplantation have all contributed to improved leukaemia 
survival. NPs also offer benefits in the treatment of leukaemia by 
providing sustained drug levels in the bloodstream without being 
dependent on leaky blood vessels to access the neoplastic cells as in 
solid tumours. 
The potential clinical utility of VEGF inhibition in oncology is 
not limited to solid tumours. There is growing evidence that VEGF 
and VEGFRs are expressed by a variety of leukaemias and other 
hematologic malignancies, suggesting that inhibition of VEGF or 
VEGFR signalling may have a role in the treatment of such 
conditions [227]. Several clinical trials are currently testing these 
hypotheses. Cancer cell-specific receptors/antigens that have been 
applied as targets for leukaemia therapy include CD33 (a surface 
antigen expressed on over 80 % of leukaemia blasts from acute 
myeloid leukaemia suffering patients but not on healthy cells) 
[228], CD45, CD20 (a surface antigen expressed only in normal B-
cells and B-cell lymphoma while absent on T lymphocytes and 
bone marrow), and CD13. The chimeric anti-CD20 MAb 
(rituximab) is used to treat B-cell lymphoma. Its efficacy was also 
demonstrated in the treatment of rheumatoid arthritis and 
inflammatory myositis. The humanized p67.6 anti-CD33 is 
currently used in the clinic conjugated with calicheamicin through 
an acid-labile linkage (gemtuzumab ozogamicin, Mylotarg®) for the 
treatment of relapsed acute myeloid leukaemia patients who are not 
candidates for conventional chemotherapy. 
Studies have shown that a successful targeting of leukaemia 
cells can be achieved using antibody-conjugated PNP [45, 99, 104, 
113, 129, 130, 229]. Biodegradable PLA PNP coupled to anti-CD20 
produced by Nobs et al. have shown to specifically bound and 
remained at the cellular surface of Daudi lymphoma cells 
(overexpressing CD20), and not on SKOV-3 human ovarian cancer 
cells (CD20 negative) [45]. The fact that the conjugated NPs were 
not internalized by Daudi cells was attributed to the fact that CD20 
is a tetraspan cell surface molecule, which is not internalized in 
response to antibody binding. The proposed mechanism of 
interaction between Daudi and anti-CD20 NPs is a cell surface 
clustering. Sapar and Allen have demonstrated the therapeutic 
advantage of targeting internalizing epitopos (e.g., CD19) vs. non-
internalizing epitopes (e.g., CD20). Anti-CD19-Ls were rapidly 
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internalized into human B-lymphoma (Namalwa) cells, whereas 
those targeted with anti-CD20 were not internalized. 
Administration of single intravenous doses, to severe combined 
immunodeficient mice inoculated intravenously with Namalwa 
cells, of DOX-loaded anti-CD19-Ls resulted in significantly greater 
survival times than either DOX-loaded anti-CD20-Ls or non-
targeted Ls [99, 104, 128, 130]. The toxicity and therapeutic 
activity of anti-CD19 Ls have shown to be related with the drug 
release rate obtained from different liposomal formulations. Ls with 
the slowest drug release rates showed no toxicity and a superior 
therapeutic activity than other formulations when targeted with 
anti-CD19 [129]. Biotinylated antibodies specific for the CD3 
antigen on lymphocytic cells were conjugated onto gelatine NPs by 
a neutravidin-biotin-complex formation, and tested for cell type-
specific targeting into CD3-positive human T-cell leukaemia cells 
and primary T lymphocytes. Uptake rates of about 84 % into T-cell 
leukaemia cells were observed through a selective receptor-
mediated endocytotic process [113]. PEGylated Ls containing DOX 
(PL-DOX) were conjugated with HB22.7, an anti-CD22 MAb that 
mediates internalization when bound to CD22, and tested in non-
Hodgkin’s lymphoma xenograft-bearing mice. The DOX-loaded 
PEGylated ILs exhibited greater cytotoxicity (3.1- to 5.4-fold 
decrease in IC50) vs. PL-DOX in CD22-expressing cell lines, 
whereas the cytotoxicity was the same in CD22-negative cell lines. 
Comparison of the biodistribution of PL-DOX vs. DOX-loaded 
PEGylated ILs at 24 h post-treatment shows that the greatest DOX 
accumulation occurs in the tumour and that accumulation is 1.8-
fold greater for the ILs compared with PL-DOX treated mice. The 
spleen also showed more DOX accumulation with the IL treatment 
compared with the PL-DOX treatment (1.6-fold increase). Also, the 
ILs were more effective at reducing tumour volume than was PL-
DOX at all dose levels with a 1.8- to 2-fold decrease in tumour 
volume between corresponding single-dose treatment groups. A 
highly significant reduction in tumour volume was seen in the 
group treated with three doses of 8 mg/Kg DOX-loaded PEGylated 
ILs: 45-fold greater reduction in tumour volume when compared 
with PL-DOX, and 60-fold reduction when compared with control 
mice [132]. An alternative, where a specific orientation of the 
antibody is not necessary, is the direct attachment of Fab’s to the 
NP surface. In an effort to develop a clinically acceptable DOX 
formulation, stealth® ILs were targeted against the B-cell antigen 
CD19, via a whole HD37 MAb, vs. its HD37 Fab’s fragment or an 
HD37-c-myc-cys-His5 single chain Fv fragment (scFv, HD37-
CCH) directed against the same epitope [131]. Compared to the 
untargeted Ls, stealth® ILs showed increased binding in vitro to 
CD19-expressing Raji cells, and when loaded with DOX, increased 
cytotoxicity against Raji (CD19+), but not Molt4 (CD19−) cells. 
Biodistribution studies in naïve and Raji-bearing mice showed that 
the DOX-loaded and the HD37 Fab’s surface decorated stealth® ILs 
exhibited the longest circulation half-life of the conjugated Ls 
tested, and the same long circulation half-life as DOX-loaded 
stealth® Ls while the DOX-loaded stealth® ILs targeted via HD37 
MAb or HD37-CCH were cleared faster due to increased liver 
uptake. All the formulations of DOX-loaded stealth® ILs extended 
the mean survival time of Raji bearing mice compared to DOX-
loaded stealth® ILs or the free DOX. DOX-loaded and the HD37 
Fab’s surface decorated stealth® ILs, which had the longest 
circulation half-life, appeared to be slightly more effective in 
prolonging survival times than DOX-loaded stealth® ILs targeted 
via either HD37-CCH or HD37 MAb. 
5.2. Brain Targeting 
Many neurotherapeutics are unsuccessful in treating central 
nervous system disorders due to their inability to reach the brain 
parenchyma when intravenously administered. Two physiological 
barriers separate the brain from its blood supply and control the 
transport of compounds: the BBB and the blood cerebrospinal fluid 
barrier. BBB is a specialized system of capillary endothelial cells 
that supplies the brain with the required nutrients for proper 
function while protecting the brain from substances which are 
neurotoxic in physiological concentrations [230]. BBB is composed 
of an inner endothelial cell monolayer which forms the wall of the 
capillary associated with perycites and astrocytes. This physical 
barrier is characterized by tight intracellular junctions and by the 
absence of fenestrations that restricts the entry of therapeutic agents 
to the brain from the periphery [231]. The blood cerebrospinal fluid 
barrier forms a second barrier separating the blood from the 
cerebrospinal fluid. It is sited at the choroid plexus epithelium and 
secretes the cerebrospinal fluid. It functions together with the BBB 
to control the internal environment of the brain [232]. The choroid 
epithelial cells form tight junctions but present fenestrations 
therefore showing a low resistance in comparison with the 
endothelial cells of the BBB and allowing the diffusion of small 
molecules [233]. Besides the higher permeability, the blood 
cerebrospinal fluid barrier not significantly increase the penetration 
of drugs into the brain due to its 1000 fold smaller surface 
compared with the surface area of the BBB [234]. 
BBB not only functions as a physical barrier but also as a 
biochemical barrier containing enzymes like peptidases along with 
several cytosolic enzymes and a particularly active efflux P-gp 
system that helps pumping drugs from the brain back into the 
bloodstream [235]. Therefore, the BBB is often the rate-limiting 
step in the permeation of drugs into the brain. It has been 
investigated that 100 % of large molecule drugs do not cross the 
BBB and only small molecule drugs with a molecular mass under 
400 Da and high lipid solubility are able to cross the BBB in 
significant amounts [236]. Consequently, very few molecules may 
be transported efficiently into the brain which may compromise the 
efficient treatment of neurological and psychiatric disorders and 
makes brain drug targeting more difficult for the pharmaceutical 
industries. Several invasive strategies have been developed to 
improve the penetration of drugs into the brain such as interstitial 
drug delivery through direct injection into the cerebral parenchyma 
and implantation of drug-loaded polymeric matrices [237-239]. 
These strategies rely on drugs diffusion which is very slow in the 
cerebral parenchyma and can cause infections and cerebral edemas 
[240], not to mention the discomfort they pose to the patient. Non-
surgical strategies such as the modification of drugs to produce 
lipophilic analogs and prodrugs [241], and the generation of a 
transient disruption of the BBB through the intracarotid 
administration of agents such as mannitol, leukotrienes, and 
vasoactive peptides have also been investigated [242, 243]. 
Active targeting of the BBB using long-circulating NPs 
represents a promising non-invasive strategy for improving drug 
delivery to brain and at the same time prevent the access of the drug 
to other body parts [47, 244-246]. By suitable tailoring the size and 
surface properties, NPs can be made to achieve ability to cross the 
BBB. Gao and Jiang tested NPs with different size ranges and 
found that although there was no significant difference on the 
function of overcoming BBB among NPs whose average diameter 
was from 100 to 400 nm, significant difference was observed when 
NP size was below 100 nm [247]. NPs overcoated with surface 
active agents (polysorbate 80, poloxamer 188) have shown the 
ability to deliver many drugs across the BBB [248-251]. The 
mechanism of delivery appears to be associated with a receptor-
mediated uptake process by the brain capillary endothelial cells 
after adsorption of apolipoprotein E or A-1 after injection into the 
blood stream [252]. Antibodies able to recognize the various influx 
transport systems expressed within the cerebral endothelial, 
including carrier-mediated transports (CMT), RME, and adsorptive-
mediated endocytosis (AME) systems can be used as targeting 
moieties. These transport systems have an essential physiological 
role in the delivery of vital substances to the brain. CMT systems 
mediate the passage of nutrients of low molecular weight through 
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specific membrane protein carriers highly expressed on the cerebral 
capillaries of the BBB. Over 20 carriers have been identified, 
including the carriers for D-glucose, monocarboxylates, amino 
acids, small peptides, etc. [253, 254]. RME provides a mean for 
selective uptake of high molecular weight molecules by specific 
type receptors. The specific receptors of the brain capillary 
endothelium were identified for low density lipoproteins (LDL): 
insulin, insulin-like growth factors, interleukin-1, folic acid, 
tranferrin, leptin, and Fc fragment of IgG [236, 255]. However, 
receptor-mediated transcytosis (RMT) was only illustrated for 
insulin and TfRs [256, 257]. AME system is based on electrostatic 
interactions established between a positively-charged ligand and the 
negatively-charged membrane of the BBB. It has a lower affinity 
and higher capacity than RME [255]. Cationized albumin and 
cationized immunoglobulins have shown a significantly transport 
improvement when compared to native proteins [258, 259]. 
Antibody-conjugated NPs can therefore bind specifically to the 
brain capillary endothelium cells, inducing an internalization 
mechanism depending on the antibody. NPs can be either 
exocytosed and hence reach the cerebral parenchyma or degraded 
within lysosomes leading to drug release into the brain tissue [47]. 
All these influx transport systems also play a key role in the growth 
of cancerous cells and consequently, they are usually overexpressed 
on tumours and therefore can also be used as targets in brain 
tumour therapies. For example, TfR is overexpressed on the brain 
capillary endothelium [260] and at the surface of proliferating cells 
such as brain tumour cells, especially glioblastoma multiforme 
[261] while, in contrast, a low level of TfR is observed on other 
healthy tissue. The ability of ILs to deliver genes within tumoural 
brain cells through TfR was studied by Zhang et al. [262]. ILs 
decorated with both 8D3 MAb, an antibody for TfR (to allow the 
crossing of the BBB by a RMT mechanism), and 83-14 MAb, an 
antibody for the human insulin receptor (to induce RME) [263], 
carrying a plasmid DNA encoding the EGFR antisense mRNA, 
were intravenously injected in mice bearing U87 brain tumours. A 
100 % increase in the survival rate was observed for the group 
treated by the plasmid mRNA-loaded-ILs in comparison to the 
saline control and the luciferase gene therapy group, therefore 
demonstrating the ability of these ILs to treat brain tumours. The 
MAb known as OX26 recognizes an extracellular domain on the 
TfR distinct from the Tf binding site and thus does not interfere 
with endogenous Tf binding. Experiments showed specific 
targeting of OX26 on the brain capillary endothelial cells in rats and 
its ability to reach the cerebral parenchyma [264, 265], therefore 
allowing the development of drug delivery systems to the brain 
using OX26 MAb. OX26- biotinylated-ILs loaded with 
daunomycin, prepared by a non-covalent (biotin-streptavidin) 
coupling procedure, revealed a two-fold higher accumulation in 
brain tissue as well as brain permeability as compared to IgG-ILs 1 
hour after intravenous administration [138]. None of several other 
tissues analyzed such as spleen, liver, heart, skeletal muscle, and 
kidney (and in sharp contrast to the brain) have shown a superior 
targeting of OX26-ILs as compared to IgG-ILs. The authors 
demonstrated that such biotinylated ILs are internalized by RME in 
vitro by cells expressing the rat TfR [266] and by-pass P-gp in 
MDR RBE4 brain capillary endothelial cells, and thereby achieved 
2- to 3-fold higher intracellular accumulation of liposomal 
daunomycin as compared to free drug [138]. 
EGFR is an attractive molecular target for the specific delivery 
of therapeutic agents to high-grade gliomas as it is frequently 
overexpressed in glioblastoma multiforme and anaplastic 
astrocytomas, but it is undetectable or weakly expressed in the 
normal brain [267]. ILs conjugated to anti-EGFR antibody have 
been proposed for boron neutron capture therapy. Cetuximab ILs 
were synthesized using a maleimido-PEG-cholesterol as an anchor 
for surface conjugation to targeted delivery of boron compounds to 
EGFR(+) glioma cells for neutron capture therapy [139]. Much 
greater (8-fold) cellular uptake of boron was obtained using 
cetuximab-ILs in EGFR(+) F98EGFR cells compared with non-
targeted human IgG-ILs. Also, ILs composed of nickel lipid were 
synthesized using the antibody affinity motif of protein A (ZZ) as 
an adaptor for surface conjugation of anti-EGFR antibodies to 
targeted delivery of boron compounds to EGFR-overexpressing 
glioma cells. Immunohistochemical analysis revealed that the boron 
compound was delivered effectively into the cells but not into 
EGFR-deficient glioma or primary astrocytes. Moreover, studies in 
animal models of brain tumours confirmed that both the Ls and the 
boron compound were only observed in the tumour with an 
effective delivery into glioma cells [140]. The treatment of 
intracranial U-87 MG brain tumours in nude mice with DOX-
encapsulated long-circulating Ls conjugated to the MAb 2C5 
provides a significant therapeutic benefit over control formulations, 
substantially reducing the tumour size and almost doubling the 
survival time [137]. 
Because ILs are not able for sustained release of transported 
compounds, they require frequent administrations to sustain a 
pharmacological effect [268]. ImmunoPNP with sustained release 
properties may offer an interesting alternative. PNP conjugated to 
OX26 MAb were synthesized using chitosan-PEG and chitosan-
PEG-biotin copolymers to carry a specific caspase inhibitor (Z-
DEVD-FMK), which significantly reduces vulnerability to the 
neuronal cell death but is unable to cross the BBB and to diffuse 
into the brain tissue [153]. Fluorescently-labelled NPs were 
administered systemically to mice and the brain uptake was 
observed by both fluorescent and electronic microscopy. A great 
number of OX26-immunoNPs could penetrate into the brain 
whereas the OX26-free NPs could not, suggesting the crossing of 
the BBB by RMT. These NPs combine the cationic character to 
interact with the negative charges of the brain endothelium and the 
affinity of OX26 for the TfR to trigger receptor-mediated transport 
across the BBB. Antibody-conjugated HSA NPs were prepared to 
deliver loperamide, an analgesic drug that normally does not cross 
the BBB in the brain [269]. OX26 and a transferrin receptor MAb 
(R17217) were covalently coupled to NPs using the NHS-PEG-
maleimide-5000 crosslinker. Significant anti-analgesic effects in the 
tail-flick test were observed compared to the control loperamide-
loaded HSA NPs with IgG2a antibodies therefore demonstrating 
that the loperamide-MAb-coupled HSA NPs were able to transport 
this drug and possibly other drugs across the BBB. Tsutsui et al. 
synthesized hybrid bionanocapsules (BNCs), which are hollow NPs 
that are composed of L protein (the hepatitis B virus surface 
antigen), conjugated with anti-human EGFR antibody recognizing 
EGFRvIII, a constitutively active genomic sequence deletion 
variant of EGFR overexpressed in human glioblastoma [270]. The 
hybrid BNCs were efficiently delivered to glioma cells but not 
normal glial cells. Moreover, they confirmed the specific delivery 
of the hybrid BNCs to brain tumours in an in vivo brain tumour 
model. 
A long way of optimization and evaluation is still, however, 
needed before potential clinical application. Providing NPs with 
stealth properties is a complex issue that involves the optimization 
of combined parameters, such as the NP size and the surfactant 
molecular weight and amount. Stealth properties and BBB 
transportation of immunoNPs, as well as effective drug release in 
the brain parenchyma, remain to be investigated [268]. 
5.3. Inflammatory and Infectious Diseases  
One of the foremost areas of promise for targeting drug delivery 
by NPs that has so far been relatively unexploited is the treatment 
of inflammatory and infectious diseases. Large doses of the most 
common and potent drugs used are necessary to induce a 
satisfactory effect and often cause unwanted side effects when 
applied in their free form [271]. Inflammatory as well as infectious 
diseases are known to activate the immune system. Macrophages 
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are among potential cellular targets by drug-loaded NPs as they 
play a central role in the initiation and maintenance of the 
inflammatory process and act as reservoirs for microorganisms 
involved in infected diseases. Although targeting to those immune-
related cells appears rather easy due to their capacity to recognize 
and phagocytize hydrophobic particles, selective targeting to organs 
different from liver and spleen is challenging being, however, 
essential for the success of these therapies. From the therapeutic 
point of view, phagocytosis of NP-encapsulated drugs could lead to 
phagocyte apoptosis (as in the case of inflammatory diseases) or 
efficient microbial destruction, as macrophages may serve as sites 
of proliferation of microbes during some or all of the infection 
process [86]. Also, structural changes associated with the 
inflammatory process (e.g., rheumatoid arthritis, infarction, 
infections), such as the perturbation of the endothelial barrier 
integrity [272], can provide an accumulation of nanocarriers in the 
desired area (passive targeting). There is evidence in support of 
increased capillary permeability to Ls and polymeric nanospheres 
in the size range of 50-200 nm during inflammation based on 
observations in experimental animals and in humans [273-277]. 
Also, the overexpression of particular cell adhesion molecules 
(CAM) involved in leukocyte recruitment at inflammatory loci 
offers opportunities to achieve selective delivery to disease tissues 
[278] using MAb against these adhesion molecules. The induction 
of E-selectin, involved in the arrest of monocytes, neutrophils, and 
subsets of T-lymphocytes within the circulation, on endothelial 
cells is clearly associated with inflammatory and immune processes 
[279]. Therefore, antibody-conjugated NPs can present significant 
implications for the improved treatment of inflammatory diseases 
such as rheumatoid arthritis, inflammatory bowel disease, 
atherosclerosis, and multiple sclerosis, as well as bacterial and viral 
diseases such as tuberculosis, malaria, and acquired 
immunodeficiency syndrome (AIDS). 
5.3.1. Inflammatory Diseases 
Inflammation is a naturally occurring defence mechanism upon 
exposure to specific antigens, chemicals, infections, and physical 
stress. It is characterized by different events taking place at or near 
the injured area, including vascular endothelium cell (VEC) 
activation and immune-related cells like macrophage accumulation. 
Due to their critical role in the initiation and maintenance of 
inflammation that leads to tissue destruction, the direct targeting of 
macrophages by NPs can find an application in the treatment of 
diseases such as atherosclerosis where monocytes/macrophages are 
attracted to the vessel wall promoting atherosclerotic lesions and 
plaque vulnerability, restenosis and rheumatoid arthritis where 
macrophages are activated and proliferate in an abnormal way 
leading to the production of pro-inflammatory cytokines and MMP 
at the joint synovium [280], and multiple sclerosis (an 
inflammatory disease of the central nervous system) where after 
their activation, they secrete an increased amount of nitric oxide 
(NO) which has neurotoxic effects and affects the permeability of 
the BBB [281, 282]. Also, due to their capacity to reach the central 
nervous system, circulating macrophages can act as carriers for 
drug-loaded NPs representing a powerful way to treat 
neuroinflammatory diseases. 
CAMs are known to play a role in leukocyte recruitment. The 
expression of particular cell CAMs, such as ICAM-1, E-selectin, P-
selectin, and/or VCAM-1, is locally induced or enhanced at sites of 
pathological inflammation [279] in acute and chronic disorders 
including rheumatoid arthritis [283], organ ischemia-reperfusion 
injury [284], inflammatory bowel diseases [285], asthma [286], 
atherosclerosis. The overexpression of these CAMs at inflammatory 
loci offers opportunities for the development of drug delivery 
strategies to achieve selective delivery to disease tissues [271, 278]. 
MAbs against adhesion molecules have been used to inhibit 
leukocyte recruitment into areas of dermal, synovial, and lung 
inflammation [287-290]. Examples of such molecules in clinical 
development are CDP870 for the treatment of rheumatoid arthritis 
and Crohn’s disease, and CDP860 for the acute treatment of 
coronary restenosis. This has provided the platform for further 
research and development, as an approach for antibody-based 
therapy of chronic disease [105]. A promising opportunity for 
therapeutic intervention is to couple these MAbs to NPs, allowing 
the transfer of large numbers of drug molecules to an individual 
target site. 
Studies on production of PNP that have been shown to 
accumulate in vascular lesions for the prevention of restenosis [291, 
292] and for imaging and therapy of arthritis [273, 293, 294], and of 
Ls for the treatment of encephalomyelitis [295-299] and multiple 
sclerosis [300], have been until now based on passive targeting and 
targeting using peptides or glycol groups. Despite the studies 
concerning antibody-conjugated NPs are at the very beginning, 
promising initial outcomes have already been achieved. ICAM-1 
targeting offers the possibility of intracellular drug delivery, given 
that endothelial cells internalize multimeric anti-ICAM conjugates, 
within 15 to 30 min [301], and anti-ICAM nanocarriers via a 
unique, newly defined pathway, CAM-mediated endocytosis [302]. 
In addition to acting as delivery vehicles, antibody blocking of 
ICAM-1 suppresses leukocyte adhesion to endothelial cells, 
providing an anti-inflammatory benefit to the effects of drugs. Also, 
anti-E-selectin ILs loaded with dexamethasone have been tested in 
vivo and display binding and internalization in a mouse model of 
skin inflammation [141]. Dexamethasone-loaded Ls conjugated 
with anti-E-selectin antibodies were shown to be internalized by 
activated endothelial cells in vitro through E-selectin-mediated 
endocytosis in an injury model characterized by glomerular renal 
inflammation [142, 303]. These ILs not only show an accumulation 
in the inflamed kidney 3.6 times higher than non-targeted IgG Ls, 
but also reduce inflammatory gene expression without affecting 
blood glucose levels, a severe side effect of administration of free 
dexamethasone. The targeting approaches on the basis of 
endothelial cell adhesion molecules offer a possibility of selectively 
targeting the inflamed endothelium, and are an alternative approach 
in colitis therapy. Based on mechanisms of leukocyte recruitment to 
sites of inflammation, leukocyte-inspired biodegradable PEGylated 
PLGA particles conjugated with antibodies such as anti-human 
ICAM-1, anti-human VCAM-1, anti-human E-selectin, and anti-
human P-selectin that exhibit highly selective accumulation on 
inflamed endothelium in vitro and in vivo were designed by 
Sakhalkar et al. [154]. The particles exhibited: i) in vitro attachment 
efficiencies to inflamed endothelium on par with that of leukocytes; 
ii) up to 15-fold selective adhesion to inflamed endothelium under 
physiologically relevant in vitro flow conditions; iii) a 6-fold 
selective adhesion for cytokine inflamed endothelium, relative to 
non-cytokine treated endothelium, in vivo; and, iv) up to 10-fold 
enhancement in adhesion to trauma-induced inflamed endothelium 
in vivo due to the addition of the targeting ligand. 
5.3.2. Infectious Diseases 
Infectious diseases like AIDS, malaria, and tuberculosis 
continue to be one of the greatest health challenges in the world. 
The main drawbacks of conventional chemotherapy are the high 
drug doses required due to their unspecificity and subsequent 
toxicity, and the development of MDR. Macrophages act as host 
cells to many bacteria, parasites, and virus allowing the 
development of many deadly diseases. Therefore, targeting NPs to 
macrophages is particularly attractive because it allows the increase 
of drug concentration at specific sites where macrophages are 
abundant thus decreasing the systemic toxicity. 
5.3.2.1. Viral Infectious Disease: Acquired Immunodeficiency 
Syndrome (AIDS) 
In AIDS, macrophages represent a cell population of the RES 
that plays an important role in the immunopathogenesis of the 
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disease. Encouraging results of the improved delivery of antiviral 
agents to the MPS have been obtained using NPs [304]. An 
increased antiviral activity in a dose-dependent manner, as 
determined by a reduction of the human immunodeficiency virus 
(HIV) type 1 antigen production, was observed in vitro using 
poly(hexylcyanoacrylate) (PHCA) PNP loaded with the protease 
inhibitor saquinavir or the nucleoside analogue zalcitabine in 
infected primary human monocytes/macrophages when compared 
with the free drug [305]. The composition and size of PNP have 
shown a great influence on the capacity of HIV-infected 
macrophages to phagocytyze azidothymidine-loaded PNP. PHCA 
and HSA PNP with a diameter of 200 nm have delivered the 
antiviral drug more successfully [251]. Considering the high viral 
load observed in the lymphoid tissues and the fact that the viral 
replication in lymph nodes is 10-100-fold higher than that in 
peripheral blood mononuclear cells [306], the attachment of 
antibodies to NPs represents an attractive strategy to obtain an 
efficient delivery of therapeutic drugs to lymphoid tissues [144], 
therefore decreasing their viral stores. HLA-DR (human leukocyte 
antigens) is a major histocompatibility complex class II (MHC-II) 
cell surface receptor that is expressed in substantial levels by cells 
involved in the HIV infection development process such as 
follicular dendritic cells (FDC), B lymphocytes, activated CD4+ T-
cells, and antigen presenting cells like macrophages. Additionally, 
HLA-DR determinant is physically present on the virion surface 
and constitutes one of the most abundant host-derived molecules 
carried by HIV-1 [307]. Therefore, NPs bearing surface-attached 
anti-HLA-DR antibodies constitute an interesting approach to target 
specifically HIV-1 reservoirs, as well as free HIV-1 particles 
trapped in the FDC network. 
The ability of Ls bearing anti-HLA-DR Fab’ fragments at the 
end termini of PEG chains to target HLA-DR expressing cells and 
increase their accumulation in secondary lymphoid organs has been 
evaluated and compared to that of conventional Ls, sterically 
stabilized Ls, and conventional ILs [144]. Fluorescence microscopy 
studies demonstrated that sterically stabilized Ls accumulated only 
in macrophage-rich areas such as the subcapsular region of lymph 
nodes, and in the red pulp and marginal zone of the spleen. In 
contrast, sterically stabilized ILs highly accumulated in the deep 
cortex of lymph nodes which contains aggregates of B-cells and 
FDCs constituting the follicles, therefore representing a convenient 
strategy to deliver drugs in this area of the nodes inhibiting more 
efficiently HIV-1 replication. Moreover, the injection of sterically 
stabilized ILs resulted in an intense fluorescence signal in the white 
pulp of the spleen, suggesting a selective targeting of B-cells in the 
follicles, and of macrophages present in the marginal zone 
surrounding the lymphoid follicle. The use of sterically stabilized 
ILs could represent a convenient strategy to concentrate anti-HIV-1 
drugs at sites of infection, more particularly within lymphoid 
organs, therefore reducing the dissemination of HIV-1 and 
preserving the FDC microenvironment that will likely protect the 
infected host from developing the characteristic immunodefficient 
state. Bergeron et al. [143] also show that immunoliposomal 
indinavir is as efficient as the free agent to inhibit HIV-1 replication 
in cultured cells. On a tissue distribution study, they found that 
sterically stabilized anti-HLA-DR-ILs were very efficient in 
delivering high concentrations of indinavir to lymphoid tissues for 
at least 15 days post- a single subcutaneous injection to C3H mice, 
increasing by up to 126 times the drug accumulation in lymph 
nodes while free indinavir resulted in low drug levels in lymphoid 
organs. No toxicity and immunogenicity signals were observed in 
rodents after repeated administrations of liposomal formulations 
[143]. 
The improved pharmacology of immunoliposomal drugs could 
reduce the dose and frequency of administration of antivirals used 
in conventional therapy, facilitating drug compliance and limiting 
the occurrence of drug resistance. These results are very important 
as in 2009, 2.6 million people contracted the virus and there were 
1.8 million HIV/AIDS-related deaths. More than 5 million people 
in low- and middle-income countries were receiving antiretroviral 
therapy by the end of 2009, but that left more than 9 million 
untreated HIV-positive people in these countries [156]. 
5.3.2.2. Malaria 
Malaria, the most prevalent parasitic disease in the world, is a 
serious public health problem which affected 225 million people 
and accounted for 781000 deaths, mostly of children under five 
years old, in 2009 [156]. The disease, caused by Plasmodium 
species transmitted to humans by the bites of a female mosquito, is 
being controlled by using antimalarial drugs, like chloroquine (CQ) 
and more recently tafenoquine, to which the malarial parasites are 
rapidly developing resistance by enhancing the drug efflux from the 
infected cells [308]. In order to effectively control this disease, it is 
essential the development of newer strategies for treating drug-
resistant malaria with existing drugs. The most important property 
of a nanocarrier in the context of malaria is the ability to remain in 
the blood stream for a long period of time in order to improve the 
interaction with infected red blood cells and parasite membranes 
[309]. 
Studies have shown that the covalent attachment of antibodies 
to Ls specifically enhanced their binding to rat erythrocytes in vivo 
and reduced their uptake by the liver and therefore can be used to 
target antimalarials to erythrocytes [146, 310, 311]. MAb F10-
bearing Ls containing CQ were produced and its efficacy was 
evaluated in mice infected with CQ-susceptible or CQ-resistant P. 
berghei [145]. CQ-loaded MAb F10-Ls were able to control not 
only the CQ-susceptibility but also the CQ-resistant P. berghei 
infections. Intravenous injection of CQ-loaded MAb F10-Ls at a 
dose of 5 mg/Kg of body weight per day on days 4 and 6 post-
infection completely cured the mice (75 % and 90 %, respectively) 
infected with CQ-resistant P. berghei. The high therapeutic efficacy 
was attributed to the high degree of specificity of MAb F10-Ls to 
the malaria-infected erythrocytes and their efficient internalization, 
and to the possible specific binding of MAb F10-Ls to free 
parasites. These characteristics conjugated with the ability of Ls to 
deliver several drug molecules at the same time to the target cells, 
provided a high concentration of the drug in infected cells sufficient 
to kill the intracellular parasite. Also CQ-encapsulated Ls 
covalently attached to anti-erythrocyte F(ab’)2 fragments showed to 
be effective in suppression of the CQ susceptible and resistant P. 
berghei infections, both in terms of reduction in parasitaemia and 
prolongation in the survival times [146, 147]. 
Although some promising results have already been obtained, 
antibody-conjugated NP technology applied to malaria therapy is a 
domain that it is still in the very beginning. 
5.3.2.3. Tuberculosis 
Approximately 2 billion people are currently infected with 
Mycobacterium tuberculosis worldwide, representing about 30 % of 
the global population. M. tuberculosis invades and begins its 
replication within alveolar macrophages before the bacterium 
spreads out. Therefore, tuberculosis can be seen as a disease 
involving macrophages which makes the targeting of 
macrophages by antibody-conjugated NPs a promising 
alternative in tuberculosis treatment. The same approaches 
mentioned in the previous sections for viral infectious diseases 
can be taken for the targeting of macrophages and treatment of 
tuberculosis. However, at present no studies have yet been 
developed in this area. 
5.4. Pulmonary Diseases 
Lung diseases, such as acute lung injury, cystic fibrosis, chronic 
obstructive lung disease, pulmonary hypertension, and others, could 
all benefit from targeted drug delivery systems. The lungs are 
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unique among the various body organs in that drugs, including NPs 
carrying drugs, may be delivered to them via the airways or 
intravenously. Inhalation is gaining more attention in recent years, 
due to the large alveolar surface for drug absorption, the low 
thickness of the epithelial barrier, an extensive vascularization, a 
rather low proteolytic activity in the alveolar space compared to 
other administration routes, and the absence of the first pass-
metabolism [212]. However, especially for lung diseases in which 
dysregulated endothelial function is an important component of 
pathogenesis, intravenous administration will often be the preferred 
route for NP delivery. The endothelium represents an important 
therapeutic target for controlling oxidative stress, thrombosis, and 
inflammation involved in pulmonary diseases therefore constitutive 
CAM (e.g., ICAM-1 and PECAM-1) can be ideal candidates for 
lung targeting [212]. Moreover, while monomeric immunocarriers 
exhibited avid binding to target CAMs but poor internalization in 
EC both in vitro and in vivo, multimeric nanoscale conjugates (< 
500 nm) obtained by coating beads with anti-ICAM antibodies were 
rapidly internalized in ECs via an unique endocytic process induced 
by ICAM clustering [302, 312]. It seems that utilizing NPs 
conjugated anti-CAM can be a promising delivery concept to 
endothelial cells and especially useful to treat pulmonary diseases. 
Studies performed by Wiewrodt et al. and Muro et al. showed that 
the endothelial cells internalize NPs conjugated with multiple 
copies of either ICAM-1 or PECAM-1 antibodies [302, 313]. 
Conjugates with diameter from 100 to 300 nm can enter endothelial 
cells, whereas conjugates of larger size (500 nm to 1 µm in 
diameter) remain attached to the cell surface. Therefore, by 
modulating the size of anti-CAM conjugate carriers, the drugs can 
be targeted to the surface of endothelial cells or to their interior. 
Anti-ICAM-conjugated PLGA PNP were tested in vitro and in vivo 
by Muro et al. to measure their targeting ability to the lung [149]. 
The anti-ICAM PNP rapidly and specifically bound to tumour 
necrosis factor-activated ECs in a dose-dependent manner at both 
static and physiological shear stress conditions, and bound to ECs 
and accumulated in the pulmonary vasculature after intravenous 
injection in mice. Anti-ICAM PNP displayed markedly higher EC 
affinity vs. naked anti-ICAM (Kd ≈ 80 pM vs. ≈ 8 nM) in cell 
culture and, probably because of this factor, higher value and 
selectivity of pulmonary targeting. Maruyama et al. have produced 
long-circulating ILs which can effectively bind to the lung in vivo 
by conjugation of 34 MAb, highly specific MAb to pulmonary 
endothelial cells, directly to the PEG terminal [119]. They found 
that the efficiency of IL binding to the target depended on the 
antibody density. The final number of antibody per L varied from 0 
to 74, but the average size of the ILs stayed approximately the same 
(90 - 130 nm in diameter). The results show that lung binding 
reached a plateau at about 30 MAb per L with a further increase in 
antibody content resulting in an increase in liver uptake. 
5.5. Other Therapeutic Applications 
Thrombosis is the formation of a blood clot inside a blood 
vessel, obstructing the flow of blood through the circulatory system. 
When a blood vessel is injured, the body uses platelets and fibrin to 
form a blood clot and prevent blood loss. In people admitted to 
hospital, thrombosis is a major cause for complications, and can 
often lead to loss of capacity and occasionally death. The main 
function of tissue plasminogen activator (tPA) is the proteolytic 
activation of plasminogen into plasmin, the form capable of 
breaking down blood clots. Currently, tPA is administered 
intravenously after myocardial infarction and stroke to ensure 
blood-clot dissolution. One problem associated with such treatment 
is the systemic toxicity of tPA, which can act upon plasminogen 
both in circulation and at the clot site, generating systemic plasmin 
and rendering the patient highly vulnerable to haemorrhaging. By 
conjugation of a fibrin-specific antibody to NPs it is possible to 
directly deliver tPA to the clot site. Yurko et al. covalently attached 
tPA and antifibrin antibody to polystyrene NPs, and an in vitro 
fibrinolysis assay showed that the tPA-antibody-NP conjugate were 
only slightly less potent than free tPA [314]. Moreover, tPA activity 
in the absence of clots was more than 3-fold less than that of the 
free enzyme. This system could therefore become a promising 
agent for thrombolytic treatment because the NPs can be expected 
to dissolve clots at approximately the same rate as free tPA, while 
simultaneously cleaving much less plasminogen in the circulation, 
thus lowering the risk of haemorrhage. 
6. CONCLUSIONS, CHALLENGES AND PERSPECTIVES 
Antibody-conjugated NPs are a rapidly evolving research field 
with tremendous clinical perspectives. Despite the vast efforts 
devoted to their development and some success already achieved, 
MAbs-conjugated NPs still encounter many challenges and 
limitations. For clinical success, it is essential to continue the 
research in interdisciplinary areas of molecular and cellular 
immunology, proteomics, intracellular trafficking, material science, 
biology, mechanical, and chemical engineering. 
Further investigations are necessary to find other target cells 
and cell molecules and increase the knowledge on specific and 
disease-related adhesion mechanisms. A great contribution is the 
new technologies used in antibody production that can be 
engineered to bind to their target with high affinity and improved 
cell penetration. New tracking studies currently being performed 
provide insights into particle behaviour in complex biological 
environments. However, a better understanding of these processes, 
including their transport in the blood circulation, cellular 
recognition, translocation into the cytoplasm, and final fate in the 
target cell is needed to rational improve the particle design to 
increase the therapeutic index of the targeting nanocarriers. 
Controlling and tailoring the physicochemical properties of NPs 
and their behaviours in various conditions is also a key to success. 
The materials used for NP fabrication have to be chosen carefully to 
ensure the safety of the system. Moreover, the long-term effects of 
various nanoparticulate systems are not well known and have to be 
well assessed before moving further in their development and 
applications. Another issue that must be addressed and requires 
further investigation on the already known NP production methods 
as well as the development of new techniques is the difficulty, 
costs, and safety of scaling-up. 
Although studies in murine models are important, problems 
when attempting to translate potential therapies to humans are 
expected to occur due to the differences in biology of murine and 
humans including the mechanisms of NP clearance. Nevertheless, it 
is tempting to hope that, in the near future, targeted drug delivery 
using antibody-conjugated NPs translates from initial successes 
reported in laboratory animals to medical practice. 
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ABBREVIATIONS 
AME = adsorptive-mediated endocytosis 
BBB = blood brain barrier 
BNCs = bionanocapsules 
Antibody-Conjugated Nanoparticles for Therapeutic Applications Current Medicinal Chemistry, 2012 Vol. 19, No. 1     19 
BSA = bovin serum albumin 
CAM = cell adhesion molecule  
CDR = complementary determining regions 
CEA = carcinoembryonic antigen 
CMT = carrier-mediated transport 
CPNP = calcium phosphosilicate nanocomposite particles  
CQ = chloroquine 
DOX = doxorubicin 
DR5 = death receptor 5 
ECM = extracellular matrix proteins 
EDC = 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
EGFR = epidermal growth factor receptor 
FDC = follicular dendritic cells 
HAb = half antibody 
HAMA = human anti-mouse antibody 
HCC = hepatocellular carcinoma 
HER = human epidermal receptor 
HER-2 = human epidermal receptor-2 
HIV = human immunodeficiency virus 
HLA-DR = human leukocyte antigen complex 
HuMAbs = human monoclonal antibodies 
IC50 = half maximal inhibitory concentration 
ICAM-1 = intercellular adhesion molecule 1  
IL = immunoliposome 
L = liposome 
MAbs = monoclonal antibodies 
MDR = multi-drug resistance 
MHC-II = major histocompatibility complex class II 
MMP = matrix metalloproteinase 
MPS = mononuclear phagocyte system 
MT1-MMP = membrane type 1-matrix metalloproteinase  
MuMAbs = murine monoclonal antibodies 
NHS = N-hydroxysuccinimide 
NPs = nanoparticles 
NSCLC = advanced non-small cell lung cancer 
PCAM = platelet endothelial call adhesion molecule  
PCL = poly(ε-caprolactone) 
PEG = poly(ethylene glycol) 
P-gp = P-glycoprotein 
PHCA = poly(hexylcyanoacrylate) 
PL-DOX = PEGylated Ls containing DOX 
PLA = poly(lactic acid) 
PLGA = poly (lactic-co-glycolic acid) 
PM = polymeric micelles 
PNP = polymeric nanoparticles 
PVA = poly(vinyl alcohol) 
RES = reticuloendothelial system 
RME = receptor-mediated endocytosis 
RMT = receptor-mediated transcytosis 
SA = streptavidin 
scFv = single-chain antibody Fv fragment  
Tf = transferrin 
TfR = human transferrin receptor 
TfR = transferrin receptor 
tPA = tissue plasminogen activator 
VCAM-1 = vascular cell adhesion molecule-1  
VEC = vascular endothelium cell 
VEGFR = vascular endothelial growth factor receptor  
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